University of Kentucky

UKnowledge
Theses and Dissertations--Pharmacy

College of Pharmacy

2013

BIOSYNTHETIC PATHWAY OF THE AMINORIBOSYL COMPONENT
OF LIPOPEPTIDYL NUCLEOSIDE ANTIBIOTICS
Xiuling Chi
University of Kentucky, xchi22@gmail.com

Right click to open a feedback form in a new tab to let us know how this document benefits you.

Recommended Citation
Chi, Xiuling, "BIOSYNTHETIC PATHWAY OF THE AMINORIBOSYL COMPONENT OF LIPOPEPTIDYL
NUCLEOSIDE ANTIBIOTICS" (2013). Theses and Dissertations--Pharmacy. 23.
https://uknowledge.uky.edu/pharmacy_etds/23

This Doctoral Dissertation is brought to you for free and open access by the College of Pharmacy at UKnowledge. It
has been accepted for inclusion in Theses and Dissertations--Pharmacy by an authorized administrator of
UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.

STUDENT AGREEMENT:
I represent that my thesis or dissertation and abstract are my original work. Proper attribution
has been given to all outside sources. I understand that I am solely responsible for obtaining
any needed copyright permissions. I have obtained and attached hereto needed written
permission statements(s) from the owner(s) of each third-party copyrighted matter to be
included in my work, allowing electronic distribution (if such use is not permitted by the fair use
doctrine).
I hereby grant to The University of Kentucky and its agents the non-exclusive license to archive
and make accessible my work in whole or in part in all forms of media, now or hereafter known.
I agree that the document mentioned above may be made available immediately for worldwide
access unless a preapproved embargo applies.
I retain all other ownership rights to the copyright of my work. I also retain the right to use in
future works (such as articles or books) all or part of my work. I understand that I am free to
register the copyright to my work.
REVIEW, APPROVAL AND ACCEPTANCE
The document mentioned above has been reviewed and accepted by the student’s advisor, on
behalf of the advisory committee, and by the Director of Graduate Studies (DGS), on behalf of
the program; we verify that this is the final, approved version of the student’s dissertation
including all changes required by the advisory committee. The undersigned agree to abide by
the statements above.
Xiuling Chi, Student
Dr. Steven Van Lanen, Major Professor
Dr. Jim Pauly, Director of Graduate Studies

BIOSYNTHETIC PATHWAY OF THE AMINORIBOSYL COMPONENT OF
LIPOPEPTIDYL NUCLEOSIDE ANTIBIOTICS

DISSERTATION

A dissertation submitted in partial fulfillment of the
requirements for the degree of Doctor of Philosophy in the
College of Pharmacy
at the University of Kentucky

By
Xiuling Chi
Lexington, Kentucky
Director: Dr. Steven Van Lanen，Professor of Pharmaceutical Science
Lexington, Kentucky
2013
Copyright © Xiuling Chi 2013

ABSTRACT OF DISSERTATION

BIOSYNTHETIC PATHWAY OF THE AMINORIBOSYL COMPONENT OF
LIPOPEPTIDYL NUCLEOSIDE ANTIBIOTICS

Several lipopeptidyl nucleoside antibiotics that inhibit bacterial translocase I (MraY)
involved in peptidoglycan cell wall biosynthesis contain an aminoribosyl moiety, an
unusual sugar appendage in natural products. A-90289 and muraminomicin are the
two representative antibiotics that belong to this family. Bioinformatic analysis of the
biosynthetic A-90289 gene clusters revealed that five enzymes are likely involved in
the assembly and attachment of the aminoribosyl unit. These enzymes of A-90289
are functionally assigned by in vitro characterization. The results reveal a unique
ribosylation pathway that highlighted by uridine-5′-monophosphate as the source of
the sugar, a phosphorylase strategy to generate a sugar-1-phosphate, and a primary
amine-requiring nucleotidylyltransferase that generates the NDP-sugar donor.
Muraminomicin, which has a structure similar to A-90289, holds the distinction in that
both ribose units are 2-deoxy sugars. The biosynthetic gene cluster of
muraminomicin has been identified, cloned and sequenced, and bioinformatic
analysis revealed a minimum of 24 open reading frames putatively involved in the
biosynthesis, resistance, and regulation of muraminomicin. Similar to the A-90289
pathway, fives enzymes are still likely involved in the assembly of the
2,5-dideoxy-5-aminoribose saccharide unit, and two are now functionally assigned
and characterized: Mra20, a 5′-amino-2′,5′-dideoxyuridine phosphorylase and Mra23,
a UTP:5-amino-2,5-dideoxy-α-D-ribose-1-phosphate uridylyltransferase. The
cumulative results are consistent with the incorporation of the ribosyl appendage of
muraminomicin via the archetypical sugar biosynthetic pathway that parallels
A-90289 biosynthesis.
KEYWORDS: Aminoribosyl unit, lipopeptidyl nucleoside antibiotics, peptidoglycan cell
wall, biosynthetic gene cluster, ORF enzymes
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Chapter one: Introduction

1.1. Significance of natural products

The use of natural products has been the single most successful strategy in the
discovery of novel medicines [1,2]. Not only have numerous medical breakthroughs
been achieved based on compounds of natural origin, natural product compounds
also represent a large share of the market [3]. The primary reasons why natural
products have been always important for the pharmaceutical industry is: the ability to
continue to inspire synthetic and analytical chemists [4,5]; remaining a major source
of human medicines [6]; leading to important biological insights [7,8] and potentiality
of many more natural products to discover [9,10,11]. Although the discovery of new
natural products has been in decline over the past two decades, natural products still
play an highly predominant role as sources of new drugs from 1981 to 2010 [12].

In general, among all drugs, almost half of new molecular entities in last 30 years
were inspired from natural products, including the natural product itself,
semi-synthetic modifications and pharmacophore-based synthesis [12]. Meanwhile,
the other half of new molecular entities were from synthetic origin. As for the drugs to
kill different kinds of bacteria, over 75% of antibacterial compounds were derived from
natural products [12]. Therefore, based on the overview of the reported data hitherto,
it turns out natural products play an even more crucial role to fight against infectious
diseases.

1.2. Discovery of new antibiotics

Although antibiotics have revolutionized medicine, new antibiotics have been in
constant need over the past 70 years [13]. Many infectious and parasitic diseases
have emerged and re-emerged with the worldwide environmental change and
1

migration. Therefore, a rapidly increasing death rate has been realized due to
infectious bacterial diseases, which has also been correlated with the occurrence of
multiple drug resistant (MDR) pathogens. MDR pathogens have become a critical
public health problem in both hospital and community settings [14]. Almost 2 million
Americans per year develop hospital-acquired Methicillin-resistant Staphylococcus
aureus (MRSA) infections in the United States, resulting in ~16,000 annually. In total,
nearly 100,000 deaths per year are due to infections disease, the majority of which
are due to MDR pathogens [15]. As for community acquired MRSA, there has been an
increase of 40% of new cases of resistance from 1999 to 2009 [16]. Similar problems
are surfacing throughout the world. For example, tuberculosis (TB), a disease
primarily caused by Mycobacterium tuberculosis, has been reported to be the cause
of 1.7 million deaths and 9.4 million new TB cases in 2009 alone, with the occurrence
of drug resistance steadily increasing [17].

At the same time, new antibiotic development has slowed dramatically and even
stopped due to market withdrawal and regulatory disincentives. Over the past 30
years there has been a dramatic decrease in FDA-approved systemic antibiotics and
right now no new molecular entities (NME)are in phase III [13,18,19]. There is
therefore, a seriously need to find new antibiotics with new structures and/or new
targets to fight infectious disease.

Historically, antibiotics have been discovered based on whole-cell experiments
examining cell growth inhibition, and the specific targets then identified. As a results,
targets for antibiotic action have been classified into four major classes: bacterial cell
wall biosynthesis; bacterial protein biosynthesis; DNA replication; and folate
coenzyme biosynthesis [13][20]. Our lab focused on the activity-based approach
which includes a high throughput enzyme assays with a target enzyme for the
discovery of potential inhibitors. The main enzyme that we have focused on is
bacteria translocase I, one of the key enzymes involved in peptidoglycan cell wall
biosynthesis.
2

1.3. Biosynthesis of peptidoglycan cell wall

An essential process for bacterial cell survival and a well known targets for the design
of antibiotics is the peptidoglycan biosynthetic pathway [21,22][23]. Bacterial
peptidoglycan and its precursors were first identified and characterized in the 1940s
[24]. This pathway results in the production of the cell wall peptidoglycan layer, which
contains polymerized glycan chains with cross-linked peptides. The peptidoglycan
layer is comprised of alternating N-acetylglucosamine (GlcNAc) and N-acetylmuramic
acid (MurNAc) glycan moities connected through β-1,4-linked polysaccharide peptidyl
bonds. The general structure of pentapeptide attached to side chain of MurNAc is
L-Ala-γ-D-Glu-X-D-Ala-D-Ala where X is either L-Lys or meso-diaminopimelic acid
(DAP). L-Lys is usually found in most Gram-positive bacteria, whereas DAP is often
found in most Gram-negative bacteria. A 3-amino group of the Lys/DAP residue at
position 3 and the D-Ala residue at position 4 of a second strand form the peptide
linkage resulting in cross-links peptidoglycan of cell wall (Fig 1.1) [25,26]. The
assembly of the cell wall occurs in three stages - 1) polymerization of the disaccharide
and peptide side-chain within the cytosol, 2) the lipid cycle wherein the precursor is
linked to a lipid carrier prior to leaving flipped to the outside, and 3) the cross-linking
stage outside the cell leading to the rigid and essential cell wall structure [27].

Figure 1.1. Structure of peptidoglycan.[26]
In the cytosolic stage, Uridine-5′-diphosphate (UDP)-sugars are the biosynthetic
precursors for the biosynthesis of all cell wall components. The activated
3

monosaccharide

uridine-5-diphospho-N-acetylglucosamine

(UDP-GlcNAc)

and

UDP-N-acetylmuramic acid (UDP-MurNAc) are the starter of the building blocks for
the polysaccharide backbone of peptidoglycan. UDP-MurNAc originates from
UDP-GlcNAc by adding PEP catalyzed by MurA and MurB. A line of ATP-dependent
ligases MurC–F catalyze the addition of L-Ala, D-Glu, L-Lys or m-DAP and
D-Ala-D-Ala sequentially to UDP-MurNAc to generate UDP-MurNAc-pentapeptide,
the

final

cytoplasmic

precursor

[21,22,25][28]

(Fig

1.2).

MraY

(phospho-MurNAc-pentapeptide translocase), also known as translocase I, transfers
the sugar-pentapeptide unit onto undecaprenyl phosphate (a lipid carrier) to generate
lipid intermediate I [29]. Subsequently, lipid intermediate II is formed by adding
GlcNAc sugar onto the 4′-hydroxyl of MurNAc, catalyzed by glycosyltransferase MurG.
The precursor is then flipped from inside to outside of the cytoplasmic membrane by
a ″flippase′′ protein [29]. Lipid II further undergoes transglycosylation to generate a
glycan polysaccharide by transpeptidation, catalyzed by penicillin binding proteins
(PBPs) [30]. Undecaprenyl pyrophosphate is released from transglycosylation and
recycled by dephosphorylation [29].

Figure1.2. Biosynthesis of bacterial peptidoglycan cell wall mediated by twelve
conserved enzymes. The reaction catalyzed by each enzyme is highlighted in blue,
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and natural products that inhibit the specified enzyme are highlighted in red. a.
Diaminopimelic acid or L-α-Lys is found at this position. b. Ramoplanin also binds the
product of MurG (Lipid II) and inhibits transglycosylases. c. Glycine ligases can
precede translocase activity to yield branched peptidoglycan cell walls. d.
Vancomycin inhibits the activity of transglycosylases by binding to the substrate, Lipid
II.
Peptidoglycan cell walls are essential for the survival of all bacteria [29]. Twelve
enzyme reactions are required for the biosynthesis of peptidoglycan cell wall,
mechanisms of which haven′t been completely characterized yet (Fig. 1.2). Most of
these enzymes lack mammalian homologs, thus making cell wall biosynthesis an
intriguing target for the discovery of new antibiotics. To date, natural enzyme inhibitors
have been found for six of the biosynthetic steps. Two of the best examples
vancomycin, that inhibit transglycosylation of lipid intermediate II outside the
cytoplasmic membrane [31], and β-lactam antibiotics that inhibit the final
transpeptidation step of cell wall biosynthesis [30] (Fig. 1.2). Among these six families
of inhibitors, five of them have been clinically proven. Only the natural products,
inhibiting bacterial translocase I, haven′t been used in clinic yet, making it a unique
target for new antibiotic discovery.

1.4. MraY - Translocase I
MraY, which is also called translocase I, represents a novel target compared to
currently marketed antibiotics. The catalytic reaction of MraY is transfer of
MurNAc-pentapeptide from UDP-MurNAc-pentapeptide to undecaprenyl phosphate,
releasing UMP to give undecaprenyl-disphospho-N-acetylmuramic acid-pentapeptide
(also known as Lipid I) (Fig 1.3) [32,33]. Blast analysis of MraY shows that it has
some sequence similarity with UDP-sugars transferase enzymes from prokaryotic and
eukaryotic cell surface biosynthesis [34,35]. A mechanism of an active site
nucleophile involved in either one-step or two-step reaction has been proposed.
Isotope exchange experiments with S. aureus translocase I by Neuhausand
co-workers confirmed that the MraY-catalysed reaction is a two-step reaction, wherein
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a nucleophile forms a covalent intermediate within the reaction[36]. This reaction
starts the lipid cycle of cell wall biosynthesis and precedes translocation of the
peptidoglycan cell wall component across the lipid membrane.
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Figure 1.3.Reaction catalyzed by MraY.MraY, a transmembrane protein, catalyzes the
formation of undecaprenyl-disphospho-N-acetylmuramic acid-pentapeptide as the
first step in the lipid cycle of peptidoglycan cell wall biosynthesis. a: L-α-Lys or
diaminopimelic acid.
The transferase activity catalyzed by MraY was first discovered in 1965 [37]. However,
the gene for MraY was not identified until 1991 when over-expression of the E. coli
gene resulted in increased transferase activity relative to the wild-type strain [33].
Subsequent insertional inactivation of the mraY gene in E. coli resulted in a lethal
phenotype with early growth characteristics very similar to that of other mutant E. coli
strains containing inactivated genes involved in peptidoglycan biosynthesis [38]. In
addition to the gram-negative bacteria E. coli, the mraY gene was shown to be
essential for the viability of the gram-positive bacteria Streptococcus pneumonia [39].
Based on bioinformatics analysis of the currently available 879 sequenced microbial
genomes, a single copy of the essential mraY gene is readily identifiable by sequence
similarity, and there are no reports of genetic redundancy of translocase activity [29].

It has been predicted that MraY is a trans-membrane protein with ten α-helical
regions, five cytoplasmic segments and six periplasmic segments. Ten α-helices are
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likely to form the hydrophobic tunnel that would correspond to the binding domain of
undecaprenol phosphate. Five cytoplasmic segments are arranged like finger ends,
bearing key amino acids required for both nucleotide substrate recognition and
reaction catalysis (Fig 1.4a)[26]. Bouhss and co-workers identified MraY structure
taking advantage of a β-lactamase fusion system with both enzymes purified from E.
coli and S. aureus [40]. Due to the problems associated both with the preparation of
substrates and the enzyme, biochemical characterization of MraY has been limited.
However, preliminary biochemical characteristics from crude preparations of MraY
from soluble membrane fractions have showed that Mg2+ is one of the crucial
requirements for MraY activity [25]. Recently, recombinant E. coli MraY has been
partially purified by using an engineered C-terminus His6-tag, but the activity was
significantly reduced compared to crude preparations [41]. Furthermore, Bacillus
subtilis MraY enzyme has been isolated to apparent homogeneity and shown to be
active, however, similar to E. coli MraY, the specific activity and kinetic constants
were inferior compared to crude preparations [42]. In spite of this reduced activity,
site-directed mutagenesis was used to identify three Asp residues important for
activity, Asp-115, Asp-116 and Asp-267. These three aspartic acid residues were
very strictly conserved and might function as an active site nucleophile: Asp-115 and
Asp-116 may form a binding site for Mg2+and Asp-267regarded as the active site
residue

used

in

the

formation

of

a

covalent

enzyme-phospho-N-acetylmuramyl-pentapeptide intermediate (Fig 1.4b) [26,41].
Enzyme activity can be lost by replacing of each of three Asp residues by Asn
[41,43]. These results were consistent with the earlier kinetic analysis with S. aureus,
which suggested a double displacement mechanism [44].
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(a)

(b)

Figure 1.4. MraY structure and active site model.(a) Predicted catalytic aspartate
residues are shown in yellow circles; amino acid mutations at specific sites in green
circles are shown to have resistant activity to protein E.[45] (b) Model for active site
and first chemical reaction of MraY.[26]

In addition, the two-dimensional membrane topology has been analysed by
cross-linking to confirm bioinformatics prediction of membrane spanning regions
shown in Fig 1.4a. This data is consistent with the conserved critical Asp loops within
the active site of MraY being found on the cytoplasmic side of the lipid bilayer.
However, the tertiary structure of MraY is still not known.
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1.5. MraY – Translocase I Inhibitors

Since the identity of MraY was discovered, great efforts have been made to identify
effective MraY inhibitors during the past two decades. This has led to the discovery of
three different kinds of structural compounds that have the ability to inhibit MraY
activity. They are: protein E, a helical protein composed of 93 amino acids; the
lipopeptides amphomycin, fruilimicin & glycinocins; and nucleoside antibiotics (Fig 1.5)
[25,32].

The first category of inhibitor is Protein E, an integral membrane protein encoded by
DNA phage ΦX-174 and leads to host cell lysis using an unclear mechanism [46,47].
Recently, Tanaka showed that the minimum requirements for lysis of host cells are a
18-residue peptides with the wild-type sequences of protein E. Also, the specific
amino acids within and at the boundaries of this 18-membered helix were shown to be
important for activity [45].The second category of inhibitor is amphomycin, fruilimicin
and glycinocins. They are cyclic lipopeptide compounds that inhibit MraY activity by
formation of undecaprenyl phosphate complexes in the presence of Ca2+, a
mechanism analogous to the mode of action of vancomycin and teichoplanin [48,49].
The structures of friulimycins and glycinocins have been identified similar to
amphomycin except minor modified residues [50,51]. Amphomycin is very active
against Gram-positive bacteria streptococci and enterococci [52,53].

The last category of inhibitor, nucleoside antibiotics, is comprised of a large group of
compounds that are categorized based on signature variations of the structure. More
specifically, nucleoside antibiotics is classified into four families, including
lipodisaccharyl nucleosides, lipopeptidyl nucleosides, peptidyl nucleosides, and
glycosyl-peptidyl nucleosides (Fig 1.5). A uridine (or dihydrouridine) component can
be found in all these classes of compounds. The variable structural components of
each group of nucleoside antibiotics lead to slight variations in the specific mechanism
of inhibitor. For example, the tunicamine residue of tunicamycin, one of members of
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lipodisaccharyl nucleosides, is a structural mimic of disphospho-residue of
UDP-MurNAc pentapeptide and it is a competitive inhibitor of MraY [21,34].
Mureidomycin, a lipopeptidyl nucleoside, have been shown to be competitive
inhibitors against UDP-N-MurNAcpentapeptide [54,55]. On the other hand, the
glycosyl-peptidyl-nucleoside antibiotic A-500359A has been shown to be a
noncompetitive inhibitor against UDP-MurNAc pentapeptide residue [42]. Even
though it is possible that the variations in mechanism of inhibition may be due to
variability associated with the preparation and assay of MraY, it is certain that the
nucleoside antibiotics described herein selectively inhibit the MraY- catalyzed reaction
[25,32].

Figure 1.5. Inhibitors of MraY.

We have been studying the biosynthesis of several families of nucleoside antibiotics
that inhibit the enzyme MraY involved in peptidoglycan cell wall biosynthesis [26],
and all of these antibiotics contain unusual sugar appendages. The lipopeptidyl
nucleoside family of MraY inhibitors, which includes A-90289s from Streptomyces sp.
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SANK 60405 [56], caprazamycins from Streptomyces sp. MK739-62F [57],
FR-900493 from Bacillus cereus No. 2045 [58][59], and muraymycins from
Streptomyces sp. NRRL 30471 [60], contain an aminoribosyl moiety—a
5-amino-5-deoxyribose—attached via an O-glycosidic bond to a heptofuranose
nucleoside component, 5′-C-glycyluridine (Fig1.6). We will focus on A-90289 and
muraminomicin from Streptosporangium sp. lipopeptidyl nucleoside antibiotics
biosynthesis in this thesis (Fig 1.5). Structure-activity relationship studies using
simplified synthetic analogues of these compounds have revealed the aminoribosyl
moiety [61], and specifically the primary amine functionality [62], is critical for optimal
antibiotic activity.

Figure 1.6. Structure of representative lipopeptidyl nucleoside antibiotics containing
an aminoribosyl moiety.
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1.6. Glycosidic residues play a critical role in biological function of antibiotics

Glycosylation is a common modification found in several microbial natural products of
therapeutic value, and the sugar appendage typically has a profound effect on the
biological activity [63,64]. The critical role of sugar residues in their activity opens up a
large field for developing new glycosidic antibiotics, and vancomycin and bleomycin
are two of the most illustrative examples (Fig 1.7)[65,66].

Vancomycin, the structure of which shown in Fig 1.7, is one of the glycopeptide
antibiotics of last resort in the treatment of gram-positive bacterial infections. It
consists of a core heptapeptide with attached saccharide moieties, one of which is the
deoxyaminosugar vancosamine [67]. Sugar residues help to confer water solubility for
the compounds with aromatic residues and the disaccharides are important in
mediating back-to-back dimerization of glycopeptides [68][69]. With a disaccharide in
the structure, the activity of vancomycin is increased by 50-100 times. Nevertheless, if
an additional amino-sugar is added to vancomycin to generate a derivative, the
activity will be promoted by 1000 times [70,71]. Bleomycin, used as an antitumor drug
in the clinic, also exhibits antimicrobial activity against infections by both
Gram-positive and Gram-negative bacteria [65,66]. It has been demonstrated that
bleomycin works by cleavage of DNA and RNA strandunder the effect of Fe2+ and
oxygen regents [72][73,74]. As for the disaccharide moieties in the structure of
bleomycin, previous research revealed that they play an important role in activating
belomycin by binding of oxygen and the activation and protection (as a metal ligand)
of the reactive iron-oxo or perferryl intermediate [75]. Furthermore, Natrajan proposed
that the carbohydrate moiety is involved in cell surface recognition by bleomycin [76].
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Figure 1.7. Structure of vancomycin and bleomycin. Glycosidic residues of both
compounds are marked by blue and red circle respectively.

These unusual sugar appendages are crucial for the bioactivities of many bacterial
natural products and they are typically modified resulting in many different kinds of
formats inside the compounds, such as deoxysugars, aminosugars, etc [77]. As a
result, alteration of sugar structures of these glycol conjugates via biosynthetic
engineering approaches offers a platform for making and discovering novel natural
product analogues [64]. In order to do so, it is absolutely necessary to find out how
these sugar units are modified and assembled into compounds.

1.7. Traditional strategy for ribose and glucose incorporation into compounds

The modus operandi by which sugars are generally incorporated into molecular
scaffolds such as natural products is (i) formation of a sugar-1-phosphate derived
from a glycolytic intermediate or galactose, a catalytic process that requires either a
phosphosugar mutase or an anomeric sugar kinase; (ii) conversion of the
sugar-1-phosphate to usually an NDP-sugar (also called an activated sugar), a
reaction catalyzed by a sugar-1-phosphate nucleotidylyltransferase; and (iii) transfer
of the sugar to an acceptor substrate by a glycosyltransferase to typically generate a
new O-, N-, or aryl-C-glycosidic bond (Fig 1.8). A remarkable feature of glycosylated,
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bacterial natural products is the high degree of variability and functionality that can be
incorporated into the sugar moiety by reductases, epimerases, methyltransferases,
and aminotransferases, among others—enzymatic modifications that generally occur
at the level of the activated sugar prior to the glycosyltransferase-catalyzed reaction
[63,64].

Figure 1.8. Traditional strategies for glucose incorporation into a compound.

The traditional strategy for ribose (five-membered ring sugar) is quite different from
that of other hexoses and pentoses. It starts with ribose-5-phosphate, which is
converted to 5-phospho-α-D-ribose-1-diphosphate (PRPP) by PRPP synthetase.
This activated sugar is then used as a ribose-5-phosphate donor that is transferred
to an acceptor by a phosphoribosyl transferasae. Finally, the remaining phosphate
group is hydrolyzed by phosphatase to generate a ribosylated compound (Fig 1.9).
This strategy has recently been revealed for generating glycosidic bonds with ribose
units in natural product biosynthesis. The ribosyl moiety of the aminoglycoside
antibiotic butirosin was shown to be derived from PRPP [78], from which BtrL
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transfers ribose-5-phosphate to the acceptor disaccharide neamine to generate an
O-glycosidic bond and a second enzyme BtrP catalyses dephosphorylation to form
the final trisaccharide scaffold (Fig 1.10). This tandem, enzyme-catalyzed process is
also utilized during O-ribosylation of decaprenyl-phosphate to initiate the
biosynthesis of mycobacterial arabinogalactan [79]. Along with the wealth of N- and
C-ribosides

that

originate

via

phosphoribosyltransfer

from

5-phospho-α-D-ribose-1-diphosphate (Fig 1.10) [26][80], it would appear that
ribosylation is an exception to the typical glycosylation paradigm.

Figure 1.9. Traditional strategies for ribose incorporation into a compound.

Figure 1.10. Examples of incorporation of pentose units into acceptor molecules
using 5-phospho-α-D-ribose-1-diphosphate (PRPP).
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Based on the two typical strategies for sugar units incorporation into a natural product
discussed above, we aimed to determinated how the glycosidic residues in
lipopeptidyl nucleoside antibiotics are assembled. Like the clinically-used antibiotics,
lipopeptidyl nucleoside antibiotics (A-90289 and muraminomicin) are structurally
complex compounds that are normally difficult to be synthesized economically, and
enzymatic biosynthesis offers a relatively efficient strategy to both produce and
modify the scaffolds for preliminary testing as new drug candidates. It is envisioned
that the information provided from or inspired from the sugar residue biosynthetic
studies will have crucial importance to new antibiotics discovery and ultimate lead to
therapeutic value clinically.

Copyright © Xiuling Chi 2013
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Chapter two: Biosynthetic pathway of aminoribosyl moiety of A-90289

2.1. Background

Liposidomycins, the structure of which were first reported in 1988 [81], and
caprazamycins isolated from Streptomyces sp. MK730-62F2 are prominent
members of the peptidyl nucleoside antibiotics [57]. A-90289s, which is also belong
to the liposidomycin family of peptidyl nucleoside antibiotics, were initially identified
and reported in 2010 [56]. A-90289, isolated from Streptomyces sp. SANK 60405,
have a structure of which is very similar to caprazamycins (Fig2.1). They both share
six core moieties in the structure: a 5′-glycyluridine, an aminoribose, a diazepanone,
a 3-methyl-glutaric acid, a 6-deoxyglucose and a fatty acid. A-90289 is same as
caprazamycins except that A-90289 containing sulfate group on the 2′ position
hydroxy group of 5′-glycyluridine moiety [56].

Recent studies have revealed that caprazamycin is very active against Gram-positive
bacteria, in particular against the genus Mycobacterium including Mycobacterium
tuberculosis, Mycobacterium intracellulare and Mycobacterium avium [82,83]. As for
A-90289, it was reported that the inhibitory activity of A-90289 on bacterial translocase
I was 36.5ng/ml (IC50). A-90289 is also very active against Gram-positive bacteria with
a minimum inhibitory concentration (MIC) against S. Aureus ATCC 6538P,
Streptococcus pyogenes and Enterococcus faecium of 8mg/ml, 4mg/ml and 16mg/ml,
respectively[84].

(a)
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(b)

Figure 2.1.Streptomyces sp. SANK 60405 wild type and structure. (a) Streptomyces
sp. SANK 60405 wild type strain grew on R2YE plates. (b) Structure of A-90289 and
caprazamycin.
The biosynthetic gene cluster of caprazamycin has been cloned and characterized
recently [85]. Shortly thereafter, the gene cluster of A-90289 was reported by M.
Funabashi, et al in 2010 and demonstrated that there are 41 orfs that are
responsible for the biosynthesis of A-90289 (Fig2.2) [56]. The sequence comparison
of A-90289 gene cluster and caprazamycin gene cluster showed very high similarity
(ORFs having between 80-91% sequence identities). However, there are clear
differences within the boundary regions, and of particular interest is the gene for a
sulfotransferase (LipB) that is found at the upstream boundary of the A-90289 gene
cluster and not found within the caprazamycin gene cluster, which is expected based
on structural comparisons of these two compounds.

Figure 2.2. The A-90289 biosynthetic gene cluster.All the orfs in A-90289 gene
cluster is shown in blue. The five orfs (lipP-L) that are involved in aminoribosyl
moiety incorporation is highlighted in yellow.
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The first insight into how the disaccharide core is assembled was unveiled upon
cloning of the biosynthetic gene clusters for these lipopeptidyl nucleoside antibiotics
along with liposidomycin and muraymycin [56,85,86,87], which revealed six-shared
genes encoding a putative serine hydroxymethyltransferase (shmt for the A-90289
gene cluster), an non-heme, Fe(II)-dependent dioxygenase (lipL), a putative
nucleotidylyltransferase (lipM), glycosyltransferase (lipN), aminotransferase (lipO),
and uridine phosphorylase (lipP). We initially demonstrated that LipL is a non-heme,
Fe(II)-dependent α-ketoglutarate:UMP dioxygenase that catalyzes the conversion
UMP to uridine-5′-aldehyde (1) during A-90289 biosynthesis (Fig 2.3)[88]. In turn we
proposed that uridine-5′-aldehyde (1) serves as the substrate for a putative SHMT
LipK (Serine hydroxymethyltransferase), catalyzing an aldol-type reaction using
glycine as a co-substrate to generate 5′-C-glycyluridine. We have subsequently
shownuridine-5′-aldehyde (1) is a substrate for LipK along with L-threonine to form
5′-C-glycyluridine [89]. Based on the conjecture that the most efficient overall
biosynthetic

pathway

will

be

employed,

we

subsequently

hypothesized

uridine-5′-aldehyde (1) is also an intermediate in the pathway leading to the
aminoribosyl moiety, which would necessitate aminotransfer, phosphorolysis, ribose
activation, and ribosyltransfer by LipO, LipP, LipM and LipN, respectively (Fig 2.3).
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Figure 2.3. Proposed biosynthetic pathway for the incorporation of the aminoribosyl
moiety of A-90289.

The apparent involvement of a nucleotidylyltransferase and glycosyltransferase
suggested the pathway leading to the aminoribosyl moiety does not parallel the
known ribosylation pathways that are PRPP-dependent but instead utilizes an
NDP-sugar as the activated, sugar donor. Thus, the original biosynthetic pathway for
amino-ribose moiety incorporation into A-90289 was proposed (Fig 2.3), a pathway
that follows the archetypical sugar biosynthetic paradigm described in section 1.7.

We envisioned 4 potential routes leading to the final aminoribosyl moiety attachment
based on bioinformatics analysis catalyze. Two routes would start from uridine,
wherein a phosphorylase (LipP) catalyzed the formation of a ribose-1-phosphate
intermediate. In one route: the nucleotidylyltransferase (LipM) catalyses formation of
the activated NDP-sugar, which is followed by oxidization of the primary hydroxyl
group by a putative dehydrogenase (LipV) to give the aldehyde. The ribose then
undergoes transamination by aminotransferase (LipO). The second route starting
from uridine is catalysis by the dehydrogenase (LipV) to generate the 5′-aldehyde of
20

ribose-1-phosphate, and an amine group is introduced in a reaction catalyzed by the
aminotransferase (LipO). This aminoribosyl moiety is then transferred to NTP
(nucleoside triphosphate) to form the activated sugar counterpart catalyzed by the
nucleotidylyltransferase

(LipM).

Finally

this

activated

NDP

(nucleoside

diphosphate)-sugar could be finally transferred to an acceptor to complete the ribose
incorporation by glycosyltransferase (LipN). Another two hypothetical routes would
start with UMP, which is oxidized by dioxygenase (LipL) to form uridine-5′-aldehyde,
and then converted to the ribose-1-phosphate derivative by the uridine
phosphorylase. Following transamination, the nucleotidylyltransferase (LipM)
catalyzes the formation of the amino-ribosyl-NDP sugar, which serves as the
activated sugar for transfer by the glycosyltransferase (LipN) to the acceptor to form
the final disaccharide. Alternatively, transamination could occur prior to formation of
the ribose-1-phosphate, which is then processed by LipM and LipN.

We now present the delineation of the biosynthetic pathway for incorporating this
moiety by functionally assigning four enzymes, LipP-N. Our results define a new
sugar-like pathway for ribose incorporation that does not originate from PRPP. These
results also reveal a unique O-ribosylation pathway that indeed parallels the typical
glycosylation paradigm yet with significant distinctions that are disclosed herein.

2.2. Materials and methods

2.2.1. Chemicals and Reagents

Uridine, uracil, UTP, UDP, UMP, TTP, CTP, GTP, TMP, CMP, GMP, o-phthalaldehyde
(OPA), L-Methionine, L-glutamate, L-aspartate and other amino donors were
purchased from Sigma-Aldrich (St. Louis, MO) or Promega (Madison, WI). Buffers,
salts, and media components were purchased from Fisher Scientific (Pittsburgh, PA).
Synthetic oligonucleotides were purchased from Integrated DNA Technologies
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(Coralville, IA). Wizard® Plus SV Minipreps DNA Purification Systems, Wizard® SV
Gel and PCR Clean-Up System were purchased from Promega (Madison, WI, USA).
pET-30 Xa/LIC Vector Kit was purchased from Calbiochem (San Diego. CA, USA).
InstaGene Matrix was purchased from Bio-Rad (Hercules, CA). Ni-NTA agarose was
purchased from Qiagen (Valencia, CA). Amicon Ultra 10000 MWCO centrifugal filter
was purchased from Millipore (Billerica, MA). PD-10 desalting column was
purchased from GE Healthcare (Pittsburgh, PA). DNA sequencing was performed
using the BigDye™Terminator version 3.1 Cycle Sequencing kit from Applied
Biosystems, Inc. (Foster City, CA) and analyzed at the University of Kentucky
Advanced Genetic Technologies Center.

2.2.2. Instrumentation

UV/Vis spectroscopy was performed with a Bio-Tek µQuant microplate reader using
Microtest™ 96-well plates (BD Biosciences) or a Shimadzu UV/Vis-1800
Spectrophotometer. HPLC was performed with a Waters Alliance 2695 separation
module (Milford, MA) equipped with a Waters 2998 diode array detector and an
analytical Apollo C-18 column (250 mm x 4.6 mm, 5 μm) or a semi-preparative
Apollo C-18 column (250 mm x 10 mm, 5 μm)

purchased from Grace (Deerfield, IL).

Electrospray ionization-MS was performed using an Agilent 6120 Quadrupole MSD
mass spectrometer (Agilent Technologies, Santa Clara, CA) equipped with an
Agilent 1200 Series Quaternary LC system and an Eclipse XDB-C18 column
(150mm x 4.6 mm, 5 μm, 80Å). High-resolution MS was obtained at the University of
Minnesota, Department of Chemistry Mass Spectrometry Facility. NMR data were
collected using a Varian Unity Inova 300, 400 or 500 MHz Spectrometer (Varian, Inc.,
Palo Alto, CA).
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P chemical shifts were assigned relative to phosphoric acid

standard.
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2.2.3. Bacterial Strains and Enzymes

NovaBlue GigaSingles™ Competent Cells was purchased from Calbiochem (San
Diego. CA, USA). One Shot® BL21 (DE3) Chemically Competent E. coli was
purchased from Invitrogen (Camarillo, CA). TaKaRa LA Taq® DNA polymerase with
GC Buffer was purchased from Takara Bio Inc (Otsu, Shiga, Japan), T4 DNA ligase,
NdeI, and Hind III were purchased from New England Biolabs (Ipswich, MA). Expand
long template PCR system was purchased from Roche Applied Science
(Indianapolis, IN).

2.2.4. Synthesis of uridine-5′-aldehyde, 1

The synthesis of uridine-5′-aldehyde (1) followed a previously described procedure
[88].

2′,3′-O-p-Methoxybenzylideneuridine. To a solution of uridine (2.0 g, 8.2 mmol) in dry
THF (30 mL), ZnCl2 (1.1 g, 8.2 mmol) and p-methoxybenzaldehyde (4 mL, 32.8
mmol) was added. The turbid mixture was stirred for 2 days at room temperature and
THF was removed. The product was precipitated by the addition of diethyl ether (50
mL), which was filtered, washed with water (2 × 25 mL) and diethyl ether (2 × 25 mL).
Crystallization

from

hot

water

containing

a

little

ethanol

provided

2′,3′-O-p-methoxybenzylideneuridine (2.1 g, 71%) as white solid. Mp: 205-206 °C (lit:
207-208 °C) (1). 1H-NMR (DMSO-d6, 500 MHz) (2): δ 11.40 (brs, 1H), 7.83 and 7.75
(2 × d, 1H, J = 8.0 Hz), 7.45 and 7.40 (2 × d, 2H, J = 8.5 Hz), 6.98 and 6.96 (2 × d,
2H J = 9.0 Hz), 6.06 and 5.92 (2 × s, 1H), 5.95 (2 × d, 1H, J = 3.0 Hz), 5.65 (2 × dd,
1H, J = 8.0, 2.0 Hz), 5.13 and 5.09 (2 × brs, 1H), 4.99 and 4.97 (2 × dd, 1H, J = 6.5,
2.5 Hz), 4.87 and 4.82 (2 × dd, 1H, J = 6.5, 3.0 Hz), 4.24 and 4.15 (2 × dd, 1H, J =
4.5, 3.5 Hz), 3.78 and 3.77 (2 × s, 3H), 3.65 and 3.61 (2 × m, 2H).
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Uridine-5′-aldehyde, 1. Trifluoroacetic acid (0.2 mL, 2.5 mmol) was added to an
ice-cooled solution of 2′,3′-O-p- methoxybenzylideneuridine (1.0 g, 2.76 mmol),
N,N′-dicyclohexylcarbodiimide (3.1 g, 15 mmol), and pyridine (0.04 mL, 5 mmol) in
anhydrous dimethyl sulfoxide (13 mL), and the resulting mixture was stirred at room
temperature for 16 h. Ethyl acetate (50 mL) was added to the reaction mixture and
precipitated N,N′-dicyclohexylurea was filtered off while washing with another portion
of ethyl acetate (50 mL). Combined filtrates were washed with water (2 × 50 mL),
dried (Na2SO4), and concentrated to give crude 2′,3′-O-p-methoxybenzylideneuridine
5′-aldehyde as a white solid. Without further purification, the compound was
dissolved in a solution of 90% trifluoroacetic acid (20 mL) and stored at 37 °C for 16
h and then concentrated. An aqueous solution (30 mL) of the residue was washed
with chloroform (2 × 15 mL) and ethyl acetate (20 mL). Removal of the water
afforded compound uridine-5′-aldehyde (1) (360 mg, 54% in two steps) as off-white
foam. The compound is extremely hygroscopic in nature and exists mostly in
hydrated form. 1H-NMR (D2O, 500 MHz)(3): δ 7.88 (d, 1H, J = 8.0 Hz), 5.96 (d, 1H, J
= 6.0 Hz), 5.88 (d, 1H, J = 8.0 Hz), 5.17 (d, 1H, J = 4.0 Hz), 4.37 (dd, 1H, J = 6.0, 5.5
Hz), 4.32-4.26 (1H, m), 4.00 (dd, 1H, J = 4.0, 3.5 Hz);

C-NMR (D2O, 125 MHz): δ

13

166.05, 151.74, 141.88, 102.44, 88.53, 86.17, 73.26, 69.60.
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2.2.5. Synthesis of 5′-amino-5′-deoxyuridine, 2
The synthesis of 5′-amino-5′-deoxyuridine (2) followed a previously described
five-step procedure with minor modifications [90]. Lithium azide was prepared from
sodium azide and lithium sulfate as previously described [91].

2´,3´-O-Isopropylideneuridine.To a solution of uridine (3) (10 g; 41 mmol) and

ρ-toluenesulfonic acid monohydrate (1.2 g; 7 mmol) in anhydrous DMF containing 4
Å molecular sieves was added 2,2-dimethoxypropane (20 mL, 164 mmol), and the
mixture heated at 40 °C until completion (3 hr) as monitored using TLC
(CHCl3:MeOH, 12:1). DMF was removed by rotary evaporation and the solid
re-dissolved in ethyl acetate (100 mL) and washed with water (2 × 40 mL) and
saturated sodium bicarbonate in water (2 × 40 mL). The ethyl acetate extract was
dried and the product purified by silica gel chromatography (CHCl3:MeOH, 12:1) to
yield 6.3 g (56 %) of 2´,3´-O-isopropylideneuridine.1H-NMR (CDCl3, 500 MHz): δ
9.83 (s, 1H), 9.74 (s, 1H), 7.45 (t, 1H, J = 7.0 Hz), 5.73 (d, 1H, J = 8.0 Hz), 5.68-5.60
(m, 1H), 5.05-4.97 (m, 1H), 4.96-4.91 (m, 1H), 4.28 (brs,1H), 3.90 (d, 1H, J = 11.0
Hz), 3.80 (d, 1H, J = 11.0 Hz), 1.57 (s, 3H), 1.35 (s, 3H).
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2´,3´-O-Isopropylidene-5´-O-toluenesulfonyluridine.
To a solution of2´,3´-O-Isopropylideneuridine (6.25 g, 21 mmol) in dichloromethane
(90 mL) was added pyridine (5.4 mL, 63 mmol) and p-toluenesulfonyl chloride (16.8
g, 84 mmol), and the solution stirred at room temperature until completion (24 hr) as
monitored by TLC (CHCl3:MeOH, 25:1).

Following the addition of water (50 mL),

the product was extracted with chloroform (2 x 50 mL) and washed with saturated
sodium bicarbonate in water (2 x 50 mL). After removal of chloroform and
dichloromethane by rotary evaporation, the product was purified by silica gel
chromatography

(CHCl3:MeOH,

25:1)

to

yield

7.54

g

(78

%)

of

2′,3′-O-Isopropylidene-5′-O-toluenesulfonyluridine. 1H-NMR (CDCl3, 500 MHz): δ
8.51 (s, 1H), 7.77 (d, 2H, J = 8.0 Hz), 7.34(d, 2H, J = 8.0 Hz), 7.22 (d, 1H, J = 8.0 Hz),
5.70 (dd, 1H, J = 8.0, 2.0 Hz), 5.66 (d, 1H, J = 2.0 Hz), 4.91 (dd, 1H, J = 6.0, 2.0 Hz),
4.78 (dd, 1H, J = 6.0, 3.5 Hz), 4.39-4.30 (m, 1H), 4.28-4.21 (m, 2H), 2.44 (s, 3H),
1.54 (s, 3H), 1.33 (s, 3H).
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5´-Azido-5´-deoxy-2´,3´-O-isopropylideneuridine.
To a solution of 2′,3′-O-Isopropylidene-5′-O-toluenesulfonyluridine (6.5 g, 14.8 mmol)
in DMF (30 mL) was added lithium azide (3.7 g, 75.5 mmol), and the solution heated
at 45 °C until completion (16 hr) as monitored using TLC (hexanes:ethyl acetate, 1:1).
After removal of DMF by rotary evaporation, the product was purified by silica gel
chromatography

(CHCl3:MeOH,

25:1)

to

yield

4.2

g

(92

%)

of

5´-azido-5´-deoxy-2´,3´-O-isopropylideneuridine. 1H-NMR (CDCl3, 500 MHz): δ 8.67
(s, 1H), 7.29 (d, 1H, J = 8.5 Hz), 5.76 (dd, 1H, J = 8.0, 2.0 Hz), 5.67 (d, 1H, J = 2.0
Hz), 4.98 (dd, 1H, J = 6.5, 2.0 Hz), 4.81 (dd, 1H, J = 6.5, 4.0 Hz), 4.30-4.20 (m, 1H),
3.62 (d, 2H, J = 4.0 Hz), 1.57 (s, 3H), 1.35 (s, 3H).

5´-Azido-5´-deoxyuridine.
2′,3′-O-Isopropylidene-5′-O-toluenesulfonyluridine (4.1 g, 13.3 mmol) was added to
90% TFA in water (75 mL) and the solution stirred at room temperature until
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completion (10 min) as monitored by TLC (CHCl3:MeOH, 6:1).

After drying by

rotary evaporation, the product was purified by silica gel chromatography
(CHCl3:MeOH, 6:1) to yield 2.9 g (81 %) of 5´-azido-5´-deoxyuridine.1H-NMR
(CD3OD, 500 MHz): δ 7.72 (d, 1H, J = 8.0 Hz), 5.84 (d, 1H, J = 4.5 Hz), 5.74 (d, 1H, J
= 8.0 Hz), 4.22 (t, 1H, J = 5.5 Hz), 4.10 (t, 1H, J = 5.5 Hz), 4.08-4.02 (m, 1H), 3.68
(dd, 1H, J = 13.0, 3.0 Hz), 3.60 (dd, 1H, J = 13.0, 4.5 Hz).

5′-Amino-5′-deoxyuridine, 2.
5′-azido-5′-deoxyuridine (2 g, 7.43 mmol) was suspended in anhydrous methanol (48
mL) and purged with N2. Following the addition of 10% Pd/C (0.4 g), H2 gas was
bubbled through and the solution was stirred for at room temperature until
completion (3 hr) as monitored by TLC (CHCl3:MeOH:acetic acid 1:1:1). After
filtration and drying by rotary evaporation, the product was purified by silica gel
chromatography (CHCl3:MeOH:acetic acid 1:1:1) to yield 1.7 g (96 %) of
5′-amino-5′-deoxyuridine (2).1H-NMR (CD3OD, 500 MHz): δ 7.66 (d, 1H, J = 8.5 Hz),
5.77 (d, 1H, J = 4.5 Hz), 5.71 (d, 1H, J = 8.5 Hz), 4.22 (dd, 1H, J = 6.0, 5.0 Hz), 3.99
(dd, 1H, J = 6.0, 5.0 Hz), 3.95-3.88 (m, 1H), 2.96 (dd, 1H, J = 13.5, 4.5 Hz), 2.88 (dd,
1H, J = 13.5, 7.0 Hz).
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2.2.6. Synthesis of 5′-amino-2′,5′-dideoxyuridine, 7
The synthesis of 5′-amino-2′,5′-dideoxyuridine(7) followed a previously described
two-step procedure with minor modifications [79]. Lithium azide was prepared from
sodium azide and lithium sulfate as previously described [78].

5′-Azido-2′,5′-dideoxyuridine. To a solution of 2′-deoxyuridine (0.95 g, 4.2 mmol) in
dry DMF (20 mL) was sequentially added triphenylphosphine (1.2 g, 4.6 mmol),
lithium azide (1.07 g, 22 mmol), and carbon tetrabromide (1.5 g, 4.6 mmol), and the
solution stirred vigorously at room temperature until completion (16 hr) as monitored
by TLC (CHCl3:MeOH, 15:1). After drying by rotary evaporation, the product was
purified by silica gel chromatography (CHCl3:MeOH, 15:1) to yield 0.74 g (70 %) of
5′-azido-2′,5′-dideoxyuridine.1H-NMR (300MHz, D2O): δ 7.82 (d, 1H, J = 13.5 Hz),
6.29 (t, 1H, J = 11.5Hz), 5.92 (d, 1H, J = 14.0Hz), 4.53-4.45 (m, 1H), 4.15-4.07 (m,
1H), 3.76-3.55 (m, 2H), 2.46-2.39 (m, 2H);

C-NMR (75MHz, D2O): δ 166.3 (C),

13

151.7 (C), 142.1 (CH), 102.5 (CH), 85.8 (CH), 84.7 (CH), 71.1 (CH), 51.8 (CH2), 38.3
(CH2).
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5′-Amino-2′,5′-dideoxyuridine, 7.5′-azido-5′-deoxyuridine (0.5 g, 2.0 mmol) was
suspended in anhydrous methanol (12 mL) and purged with N2. Following the
addition of 10% Pd/C (0.1 g), H2 gas was bubbled through and the solution was
stirred for at room temperature until completion (3 hr) as monitored by TLC
(CHCl3:MeOH:acetic acid 1:1:1). After filtration and drying by rotary evaporation, the
product was purified by silica gel chromatography (CHCl3:MeOH:acetic acid 1:1:1) to
yield 0.38 g (84 %) of 5′-amino-2′,5′-dideoxyuridine(7).1H-NMR (300 MHz, D2O): δ
7.67 (d, 1H, J = 13.5 Hz), 6.25 (t, 1H, J = 11.5 Hz), 5.88 (d, 1H J = 13.5 Hz),
4.55-4.35 (m, 1H), 4.08-4.00 (m, 1H), 3.20-2.90 (m, 2H), 2.50-2.38 (m, 2H);
C-NMR (75 MHz, D2O): δ 169.3 (C), 153.8 (C), 142.1 (CH), 102.6 (CH), 86.5 (CH),

13

85.2 (CH), 71.7 (CH), 42.5 (CH2), 38.2 (CH2).
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2.2.7. Cloning of genes for heterologous expression

Genes were amplified by PCR using Expand Long Template PCR System with
supplied Buffer 2, 200 μM dNTPs, 5% DMSO, 10 ng DNA template, 5 U DNA
polymerase, and 200 nM each of the separate primer pairs (Table 1). DNA templates
for PCR cloning were E. coli DH5α genomic DNA (Ecudp) or cosmid pN1 (lipP, M, O
and N genes). The PCR program included an initial hold at 94 °C for 2 min, followed
by 30 cycles of 94 °C for 10 s, 56 °C for 15 s, and 68 °C for 50 s. The gel-purified
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PCR product was inserted into pET-30 Xa/LIC using ligation-independent cloning as
described in the provided protocol to yield pET30-LipP, pET30-Ecudp, pET30-LipM,
etc (Table 2). The genes were sequenced to confirm PCR fidelity.

Table 1. List of primers used in A-90289.
Primers
lipP_for
lipP_rev
Ecudp_for
Ecudp_rev
lipO_for
lipO_rev
lipO(K282A)
_for
lipO(K282A)
_rev
lipM_for

Oligonucleotide sequence
5′-GGTATTGAGGGTCGCATGAACGAGACAATCGGGGTTG-3′
5′-AGAGGAGAGTTAGAGCCCTAGACATGGATCATCCCCG-3′
5′-GGTATTGAGGGTCGCATGTCCAAGTCTGATGTTTTTCATC-3′
5′- AGAGGAGAGTTAGAGCCTTACAGCAGACGACGCGCCG -3′
5′- GGTATTGAGGGTCGCATGTCCGTGCTGGGGCGG -3′
5′- AGAGGAGAGTTAGAGCCTCATGAGGGCTTCTTCGGTG-3′
5′-GACCTGACCGCCTTCAGCGCGGGCCTGACCAACGGCGTG3′
5′-CACGCCGTTGGTCAGGCCCGCGCTGAAGGCGGTCAGGTC3′
5′- GGTATTGAGGGTCGCATGAAGGTGTCCGTCATCATC -3′

lipM_rev
lipN_for

5′- AGAGGAGAGTTAGAGCCTCAGCACTCCGGGCATCG-3′
5′- GGTATTGAGGGTCGCATGCCCGGAG -3′

lipN_rev

5′- AGAGGAGAGTTAGAGCCTCATCGTCC-3′

Plasmids were introduced into E. coli BL21 (DE3) cells, and the transformed strains
were grown in LB supplemented with 50 μg/mL kanamycin. Following inoculation of
500 mL of LB with 50 μg/mL kanamycin, the cultures were grown at 18°C until the
cell density reached an OD600 ~ 0.5 when expression was induced with 0.1 mM IPTG.
Cells were harvested after an overnight incubation at 18 °C and lysed using a French
Press with one pass at 15000 psi. Following centrifugation the protein was purified
using affinity chromatography with Ni-NTA agarose, and the recombinant proteins
were desalted into 50 mM Tris-HCl (pH 8), 100 mM NaCl, and 5 % glycerol using a
PD-10 desalting column. The purified protein was concentrated using an Amicon
Ultra 10000 MWCO centrifugal filter and stored as glycerol stocks (40%) at -20 °C.
Protein purity was assessed as by 12% acrylamide SDS-PAGE; His6-tagged proteins
were utilized without further modifications.
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Table 2. List of plasmids constructed/used in A-90289.
Strain/Plasmid
E.coli Nova-Blue
E.coli BL21 (DE3)
pET30
pET30-lipP
pET30-Ecudp
pET30-lipO
pET30-lipM
pET30-lipN
pUWL201pw
pUWL201pw-lipM
pUWL201pw-lipO
pUWL201pw-lipO
(K282A)
pUWL201pw-lipN

Characteristics and Relevance
host for routine cloning works
host for protein expression
expression vector
lipP gene cloned to pET30
Ecudp gene cloned to pET30
lipOgene cloned to pET30
lipM gene cloned to pET30
lipN gene cloned to pET30
expression vector
lipM gene cloned to pUWL201pw
lipO gene cloned to pUWL201pw
lipO(K282A) gene cloned to pUWL201pw

References
Novagen
Novagen
Novagen
This study
This study
This study
This study
This study
This study
This study
This study
This study

lipN gene cloned to pUWL201pw

This study

2.2.8. In vitro characterization of LipP

Reactions consisted of 25 mM potassium phosphate pH 7.5, 2 mM uridine (3) or
analogue, and 100 nM LipP at 30 °C, and terminated by the addition of cold TCA to 5%
(w/v) or by ultrafiltration using a Microcon YM-3. Following centrifugation to remove
protein, the reaction components were analyzed by HPLC using a C-18
reverse-phase column. A series of linear gradients was developed from 0.1 % TFA in
5 % acetonitrile (A) to 0.1 % TFA in 90% acetonitrile (B) in the following manner
(beginning time and ending time with linear increase to % B): 0-4 min, 100% B; 4-24
min, 50% B; 24-26 min, 100% B; 26-32 min, 100% B; and 32-35 min, 0% B. The flow
rate was kept constant at 1.0 mL/min, and elution was monitored at 260 nm. LC-MS
was performed using a linear gradient from 0.1% formic acid in water to 0.1% formic
acid in acetonitrile over 20 min. The flow rate was kept constant at 0.4 mL/min, and
elution was monitored at 254 nm.

The effect of pH on LipP activity was carried out in 50 mM indicated buffer, 2.5 mM
potassium phosphate, 2.5 mM uridine (3), and 1 μM LipP for 5 min at 30 °C. The
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reactions were terminated with 0.1 M sodium hydroxide, and uracil (4) formation was
determined by UV/Vis spectroscopy with Δε290 nm = 5, 700 M-1 at pH 13. To determine
the kinetic constants with respect to the co-substrate nucleoside, reactions were
carried out in 50 mM Tris-HCl pH 9.0 consisting of saturating phosphate (1.5 mM)
and variable nucleoside (10 - 4,700 M uridine, 10 – 10,000 M 2′-deoxy-uridine (11), 8
- 800 M 5′-amino-5′-deoxyuridine (2), or 30 - 3000 M uridine-5′-aldehyde (1), and 100
nM LipP at 30 °C under initial velocity conditions. Single substrate kinetics at pH 7.5
was carried out using identical conditions except with increased LipP (730 nM).
Kinetic analysis with EcUdp was carried out with final enzyme concentrations of 100
nM at pH 9.0 and 200 nM at pH 7.5.

2.2.9. Subcloning and expression in S. lividans TK-64

Plasmids pET30-lipM, pET30-lipO, pET30-lipO(K282A) and pET30-lipN were
digested with NdeI-HindIII and the DNA fragment of the expected size was purified
and ligated to the identical sites of pUWL201pw to yield pUWL201pw-lipM,
pUWL201pw-lipO, pUWL201pw-lipO(K282A), and pUWL201pw-lipN, respectively.
The resulting plasmids were transformed into S. lividans TK-64 using PEG-mediated
protoplast transformation and plated on R2YE. After 14 hr at 28 °C, the plates were
overlaid with 1 mL of water supplemented with 200 μg of thiostrepton. Single
colonies were transferred to fresh R2YE plates supplemented with 10 μg/mL
thiostrepton, and after 4 days at 28 °C positive transformants were confirmed by
colony PCR using InstaGene Matrix from Bio-Rad and LA-Taq polymerase with GC
buffer II. A single colony was utilized to inoculate 50 mL R2YE containing 10 μg/mL
thiostrepton, grown for 2 days at 28 °C at 250 rpm, and 2 mL transferred to fresh 50
mL containing 10 μg/mL thiostrepton. Following growth for 3 days at 28 °C at 250
rpm, the cells were collected by centrifugation and washed with 10% glycerol prior to
lysis by French press and protein purification as described above.
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2.2.10. In vitro characterization of LipM

Reactions consisted of 50 mM potassium phosphate pH 7.5, 5 mM MgCl2, 2 mM
uridine (3) or analogue, 5 mM nucleotide triphosphate, 5 μM LipP, and 1 μM LipM at
30 °C, and the reaction terminated by the addition of cold TCA to 5% (w/v) or by
ultrafiltration using a Microcon YM-3. The activity of LipM was tested with
sugar-1-phosphates generated in situ from synthetic uridine (3), 2′-deoxy-uridine
(11), 5′-amino-5′-deoxyuridine (2), or 5′-amino-2′,5′-dideoxyuridine

(7) and the

cosubstrate nucleotide UTP, dUTP, TTP, rCTP, dCTP, dGTP, rGTP, dATP, or rATP.
Following centrifugation to remove protein, the reaction components were analyzed
by HPLC using a C-18 reverse-phase analytical column. A series of linear gradients
was developed from 40 mM phosphoric acid-triethylamine pH 6.5 (C) to 20%
methanol (D) in the following manner (beginning time and ending time with linear
increase to % D): 0-8 min, 100% D; 8-18 min, 60% D; 18-25 min, 95% D; 25-32 min,
95% D; and 32-35 min, 0% D. The flow rate was kept constant at 1.0 mL/min, and
elution was monitored at 260 nm. LC-MS and NMR were performed as above.

2.2.11. OPA-modification and analysis of the LipM product

Amine-containing compounds were detected by precolumn modification with
o-phthalaldehyde (OPA). Following the enzyme reaction, LipM was removed by
ultrafiltration and an equal volume of OPA solution (to 4 mg of OPA was
sequentially added 50 μL ethanol, 4.5 mL 0.1 M sodium borate pH 9.5, and 11 μL
β-mercaptoethanol) was added. The modified reaction components were analyzed
by HPLC using a C-18 reverse-phase analytical column. A series of linear gradients
was developed from 50 mM sodium acetate pH 6.0 in 5% acetonitrile (A) to 50 mM
sodium acetate pH 6.0 in 50% acetonitrile and 40% methanol (B) in the following
manner (beginning time and ending time with linear increase to % B): 0-4 min, 0% B;
4-24 min, 50% B; 24-26 min, 100% B; 26-32 min, 100% B; and 32-35 min, 0% B. The
flow rate was kept constant at 1.0 mL/min, and elution was monitored at 335 nm.
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LC-MS was performed using a linear gradient from 0.1% formic acid in water to 0.1%
formic acid in acetonitrile over 20 min. The flow rate was kept constant at 0.4 mL/min,
and elution was monitored at 335 nm.

2.2.12. Production of the LipM product for mass and NMR spectroscopy

Large scale production and isolation of the OPA-modified product was identical to
the reactions described above using 5′-amino-5′-deoxyuridine (2) and UTP as the
starting substrates with the following modifications: sodium acetate was substituted
with ammonium acetate for HPLC and a semipreparative HPLC column was used
with a flow rate of 3.5 mL/min. The peak corresponding to the product
(5′-isoindolinine-5′-deoxyribose-1′,2′-cyclic

phosphate)

was

collected

and

freeze-dried prior to spectroscopic analysis. 1H-NMR (500MHz, D2O): δ 7.72 (d, 1H,
J =7.5 Hz, H-7), 7.62 (t, 1H, J = 7.5 Hz, H-5), 7.54 (d, 1H, J =7.5 Hz, H-4), 7.50 (t, 1H,
J = 7.5 Hz, H-6), 5.90 (dd, 1H, J = 4.5, 17.5 Hz, H-′), 4.95-4.80 (m, 1H, H-2′), 4.65 (d,
1H, J =18.0 Hz, H-3), 4.53 (d, 1H, J =18.0 Hz, H-3), 4.32-4.29 (m, 1H, H-4′),
3.99-3.93 (m, 2H, H-3′, H-5′), 3.87 (d, 1H, J =15.0 Hz, H-5′);

13

C-NMR (125 MHz,

D2O): δ 171.1 (C-1), 142.3 (C-1a), 132.2 (CH-5), 130.6 (C-3a), 127.9 (CH-6), 122.9
(CH-4), 122.8 (CH-7), 100.9 (CH-1′), 78.3 (CH-2′), 78.1 (CH-4′), 71.7 (CH-3′), 52.1
(CH2-3), 42.8 (CH2-5′); 31P-NMR (202.5 MHz, D2O): δ19.05.

Large

scale

isolation

of

the

LipM

product

starting

from

5′-amino-2′,5′-dideoxyuridine(7) was carried out with HPLC using a C-18
reverse-phase semipreparative column. A series of linear gradients was developed
from 50 mM acetic acid-triethylamine pH 6.5 (C) to 50 mM acetic acid-triethylamine
pH 6.5 containing 20 % methanol (D) in the following manner (beginning time and
ending time with linear increase to % H): 0-8 min, 0% D; 8-18 min, 60% D; 18-25 min,
95% D; 25-32 min, 95% D; and 32-35 min, 0% D. The flow rate was kept constant at
3.5 mL/min, and elution was monitored at 260 nm. The peak corresponding to the
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product UDP-5″-amino-2″,5″-dideoxyribose (8) was collected and freeze-dried prior
to spectroscopic analysis.1H-NMR (500MHz, D2O): δ 7.95 (d, 1H, J = 8.0 Hz, H-5),
6.00-5.88 (m, 3H, H-4, H-1′, H-1′′), 4.45-4.33 (m, 3H, H-4′, H-3′, H-2′), 4.30-4.17 (m,
4H, H-5′, H-4′′, H-3′′), 3.33 (d, 1H, J = 13.0 Hz, H-5′′), 2.98 (dd, 1H, J = 12.5, 10.5 Hz,
H-5′′), 2.53-2.45 (m, 1H, H-2′′), 2.24-2.15(m, 1H, H-2′′);

C-NMR (125 MHz, D2O): δ

13

166.1 (C-3), 151.7 (C-1), 141.6 (CH-5), 102.5 (CH-1′′), 100.9 (CH-4), 88.3 (CH-1′),
83.2 (CH-4′′), 81.8 (CH-3′), 73.7 (CH-2′), 71.7 (CH-3′′), 69.5 (CH4′), 64.7 (CH2-5′),
41.0 (2 × CH2, 2′′ & 5′′);

P-NMR (202.5 MHz, D2O): δ -11.66 (d, J = 20.4 Hz),
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-13.67 (d, J = 17.8 Hz).

2.2.13. In vitro characterization of LipO activity

Reactions

consisted

of

50

mM

potassium

phosphate

pH

7.5,

2

mM

uridine-5′-aldehyde (1), 2 mM amine donor, 200 μM PLP, and 1 μM LipO at 30 °C,
and the reaction terminated by the addition of cold TCA to 5% (w/v) or by
ultrafiltration using a Microcon YM-3. Alternatively, PLP was eliminated from the
reaction mixture to give comparable results. HPLC analysis of the reaction was
similar to that described for LipM.

2.2.14. Site-directed mutagenesis of LipO

A K282A point mutation of LipO was generated by PCR amplification using
pET30-LipO as a template and the Expand Long Template PCR system. Reactions
were performed using the manufacturer′s provided Buffer 2 with 5% DMSO, primers
(Table 2) and the reverse complement (the engineered Ala codon is underlined), and
a PCR program consisting of an initial hold at 94 °C for 2 min followed by 20 cycles
of 94 °C for 10 s, 56 °C for 20 s, and 68 °C for 7 min. The template DNA was
digested with 10 units of DpnI for 1 h at 37 °C and transformed into E. coli DH5α
competent cells. The introduction of the correct point mutation and the sequence of
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the entire gene including 200 bp upstream and downstream were confirmed by DNA
sequencing to yield pET30-lipO(K282A).

2.2.15. In vitro characterization of LipN activity

Reactions

consisted

of

50

mM

potassium

phosphate

pH

7.5,

2

mM

5′-amino-5′-deoxyuridine (2), 2.8 µM LipP at 30 °C for 2 hours. LipP was removed by
ultrafiltration, and 86µL of the filtrate was added to a solution of 5 mM MgCl2, 2 mM
UTP, 1 mM uridine (3), 12 µM LipM, and 7 µM LipN (final volume of 100 mL) and
incubated at 30 °C for the indicated time points. HPLC analysis was performed using
a TFA mobile phase as described above.

2.2.16. Production of the LipN product for mass and NMR spectroscopy

Large scale isolation of the LipN product starting from 5′-amino-5′-deoxyuridine
(2)was carried out with HPLC using a C-18 reverse-phase semipreparative column
using the above conditions for OR25 starting from 5′-amino-2′,5′-dideoxyuridine(7)
except acetic acid-triethylamine was substituted with TFA. The peak corresponding
to the product 5′-O-(5′′-amino-5′′-deoxyribose)-uridine (9) was collected and
freeze-dried prior to spectroscopic analysis. 1H-NMR (500MHz, D2O): δ 7.73 (d, 1H,
J = 8.5 Hz, H-5), 5.89 (d, 1H, J = 8.5 Hz, H-4), 5.86 (d, 1H, J = 3.0 Hz, H-1′), 5.11 (s,
1H, H-1′′), 4.38-4.34 (m, 1H, H-2′), 4.29-4.07 (m, 6H, H-2′′, H-3′, H-3′′, H-4′, H-4′′,
H-5′), 3.80-3.71 (m, 1H, H-5′), 3.38 (d, 1H, J = 13.0 Hz, H-5′′), 3.04 (dd, 1H, J = 10,
13.0 Hz, H-5′′),

C NMR (125 MHz, D2O): δ 166.0 (C-3), 151.3 (C-1), 141.7 (CH-5),

13

107.8 (CH-1′′), 101.9 (CH-4), 90.1 (CH-1′), 81.9 (CH-3′), 78.3 (CH-3′′), 73.9 (CH-4′),
73.2 (CH-2′), 72.5 (CH-4′′), 69.1 (CH-2′′), 68.1 (CH2-5′), 43.2 (CH2-5′′).
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2.3. Results: LipP Characterization

2.3.1. In vitro characterization of LipP activity

Our previous results have demonstrated that a non-heme, Fe(II)-dependent
α-KG:UMP dioxygenase generatesuridine-5′-aldehyde (1) from UMP to initiate the
biosynthesis of the modified uridine (3) component,5′-C-glycyluridine, of A-90289 [88].
Thus, the aminoribosyl moiety was potentially derived from uridine (3),
uridine-5′-aldehyde (1) or 5′-amino-5′-deoxyuridine (2) (Fig 2.4). These hypothetical
intermediate were therefore synthesized with the expectation that one of these would
serve as a substrate for the phosphorylase LipP.

Figure 2.4. Proposed biosynthetic pathway for the incorporation of the aminoribosyl
moiety of A-90289.

Bioinformatics analysis revealed LipP has sequence similarity to proteins annotated
as

uridine phosphorylases (Udp), an enzyme family that catalyzes
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the

phosphorolysis of uridine (3) or—less efficiently—thymidine nucleosides to generate
α-D-ribose-1-phosphate and uracil (4) or thymine, respectively, to initiate nucleotide
salvage pathways (Fig 2.5)[92]. Although inactive with the 5′-monophosphorylated
nucleotide, both human and mouse Udp have been shown to have modest activity
with unnatural 5′-deoxynucleosides [93,94]. However, the potential activity of Udp
with the 5′-modifications under investigation has not been reported, so it remained
unclear as to the chemical identity of the LipP substrate.

Figure 2.5. Phosphorylase reaction catalyzed by LipP.

The lipP gene was cloned and expressed in E. coli to yield soluble protein with the
expected size (Fig 2.6). Initial activity tests using HPLC revealed uridine (3) is rapidly
converted to uracil (4) and α-D-ribose-1-phosphate by LipP (Fig 2.7 a) as expected.
In addition to the formation of the pyrimidine base, LC-MS analysis of the reaction
revealed an (M - H)- ion at m/z = 228.7 that was absent in the control (Fig 2.8 c), a
mass that is consistent with the molecular formula C5H9NO8P of the expected
productα-D-ribose-1-phosphate. Further activity tests revealed the hypothetical
pathway intermediates uridine-5′-aldehyde (1) and 5′-amino-5′-deoxyuridine (2) were
also converted to uracil (4) and the respective sugar-1-phosphate by LipP (Fig 2.7
b,c), thus warranting further kinetic investigation for LipP.
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His6-LipP

Figure 2.6. SDS-PAGE analysis of purified His6-LipP (expected MW of 52.9 kD).

(a)

(b)

(c)

Figure 2.7. Characterization of LipP by HPLC. (a) HPLC analysis using uridine (3)
after (I) 30 min without LipP, (II) 5 min reaction, (III) 30 min reaction, and (IV)
authentic uracil (4). (b) HPLC analysis using 5′-amino-5′-deoxyuridine (2) after (I) 30
min without LipP, (II) 30 min reaction, and (III) authentic uracil (4).(C) HPLC analysis
of the reaction using substrate uridine-5′-aldehyde (1) after (I) 3 hr without LipP, (II) 3
hr reaction, and (III) authentic uracil (4). A260, absorbance at 260 nm.
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(a)

(b)

(c)

Figure 2.8. LC-MS analysis of the phosphorylase reaction. (a) Mass spectrum for
the ion peak eluting at time t = 2.852 min of the reaction mixture without enzyme. (b)
Mass spectrum for the ion peak eluting at time t = 2.852 min of the EcUdp reaction.
(c) Mass spectrum for the ion peak eluting at time t = 2.852 min of the LipPreaction.

2.3.2. Kinetics characterization of LipP

The pH profile for LipP was initially examined using 5′-amino-5′-deoxyuridine (2) or
uridine (3) as a substrate and detection of uracil (4) by UV/Vis spectroscopy (Fig 2.9
a)[95], revealing an apparent optimal activity for LipP at pH = 9.0, which is
moderately higher than reported for EcUdp (pH ~ 7.5) (Fig 2.9 b) [96]. As a result,
single substrate kinetic analysis was performed at both pH 9.0 and 7.5 with all
hypothetical pathway intermediates (Fig 2.9 c-f). The extracted kinetic constants
(Table 3) revealed that LipP has comparable efficiency with 5′-amino-5′-deoxyuridine
(2) and uridine (3) at pH 9.0, thus both appear to be viable substrates in vivo.
Saturation kinetics could not be reached with uridine-5′-aldehyde (1) (Fig 2.9g), and
the relatively low first-order rate constant of k = (3.0 ± 0.5) x 10-2 min-1 suggests that
uridine-5′-aldehyde (1) is less probable as the in vivo substrate.
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3

(a)

(b)

4

(c)

(d)

(e)

(f)

pH = 7.5

pH = 7.5

(g)

pH = 9.0

Figure 2.9. Kinetic characterization of LipP. a) Assay by UV/Vis spectroscopy by
taking advantage of the different absorption profiles of uridine (3) and uracil (4) at
alkaline pH. Shown are spectra of standards are pH ~ 13. (b) pH profile using the
indicated buffers. (c) Single-substrate kinetic analysis with variable uridine (3)at pH
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9.0. (d) Single-substrate kinetic analysis with variable 5′-amino-5′-deoxyuridine (2)at
pH 9.0. (e) Single-substrate kinetic analysis with variable uridine (3) at pH 7.5. (f)
Single-substrate kinetic analysis with variable 5′-amino-5′-deoxyuridine (2) at pH 7.5.
(g) Single-substrate kinetic analysis with variable uridine-5′-aldehyde (1) at pH 9.0.
Table 3. Extracted kinetic constants for LipP and EcUdp.
Enzym
e

pH

Substratea

Km
(μM)

LipP

9.
0

Uridine (3)

87 ± 21

Thymidine
ADU (2)

7.
5
EcUdp

9.
0

2′-deoxyU(1
1)
Uridine
ADU (2)
Uridine (3)
ADU (2)

7.
5

Uridine (3)
ADU (2)

kcat
(min-1)

kcat/Km
(μM-1min1
)

Relative
efficienc
y

(1.3 ± 0.1) x 1.5
102
(2.8 ± 0.2) x 5.3 ± 0.2
1.9 x 10-3
103
(2.1 ± 0.3) x (2.6 ± 0.2) x 1.2
102
102
(3.1 ± 0.4) x (2.1 ± 0.8) x 6.8 x 10-2
103
102
NAb
NAb
(2.6 ± 0.5) x 34 ± 1.6
1.3 x 10-1
102

100

(1.3
103
(1.0
103
(1.5
103
(2.0
103

± 0.1) x 2

100

± 0.7) x 1.0
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± 0.1) x 1.1

55

± 0.4) x 1.6 x 10-1

8

± 0.2) x (2.6
103
± 0.2) x (9.7
102
± 0.1) x (1.6
103
± 0.5) x (3.2
102

0.13
80
4.5

8.7

ADU, 5′-amino-5′-deoxyuridine; 2′-deoxyU, 2′-deoxyuridine.
not applicable, non-Michaelis-Menten kinetics was observed.

a

b

2.3.3. In vitro characterization of EcUdp activity

Initial activity tests using HPLC revealed uridine (3) is rapidly converted to uracil (4)
and α-D-ribose-1-phosphate by EcUdp (Fig 2.10 b) as expected. This enzyme was
characterized in vitro with hypothetical intermediates in the biosynthesis of the
5-amino-5-deoxyribosyl moiety of A-90289. For comparisons the udp gene from E.
coli was also cloned and expressed to yield recombinant EcUdp (Fig 2.10 a). In
addition to the formation of the pyrimidine base, LC-MS analysis of the reaction
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revealed an (M - H)- ion at m/z = 228.7 that was absent in the control (Fig 2.8b), a
mass that is consistent with the molecular formula C5H9NO8P of the expected
product α-D-ribose-1-phosphate. Further activity tests revealed the hypothetical
pathway intermediates uridine-5′-aldehyde (1) and 5′-amino-5′-deoxyuridine (2) were
also converted to uracil (4) and the respective sugar-1-phosphate by EcUdp (Fig
2.10 c,d), thus warranting further kinetic investigation for EcUdp.

(a)

(b)

His6-EcUdp

(c)

4

(d)

4
2

1

Figure 2.10In vitro characterization of EcUdp with hypothetical intermediates. (a)
SDS-PAGE analysis of purified His6-EcUdp (expected MW of 32.2 kD). (b) HPLC
analysis using substrate uridine (3) after (I) 30 min without EcUdp, (II) 30 min
reaction, and (III) authentic uracil (4). (c) HPLC analysis using substrate 1 after (I) 30
min without EcUdp, (II) 30 min reaction, (III) 3 hr reaction and (IV) authentic uracil (4).
(d) HPLC analysis using substrate 5′-amino-5′-deoxyuridine (2) after (I) 30 min
without EcUdp, (II) 30 min reaction, and (III) authentic uracil (4).

2.3.4. Kinetics characterization of EcUdp

Single substrate kinetic analysis for EcUdp was performed at both pH 9.0 and 7.5
with all hypothetical pathway intermediates (Fig 2.11a). The extracted kinetic
constants (Table 3) revealed that EcUdp has comparable efficiency with
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5′-amino-5′-deoxyuridine (2) and uridine (3) at pH 9.0. Although the Km and kcat for
each respective substrate were lower for LipP relative to EcUdp, the efficiencies and
kinetic trends for both enzymes were quite comparable
(a)

(b)
pH = 9.0

pH = 7.5

kcat/Km =
-1

kcat/Km =
-1

1.1 uM-1min-1

2.0 uM min

(c)

(d)
pH = 9.0

pH = 7.5

kcat/Km =

kcat/Km =

1.0 uM-1min-1

0.16 uM-1min-1

Figure 2.11. Kinetics analysis of EcUdp. (a) Single-substrate kinetic analysis with
variable uridine (3) at pH 9.0. (b) Single-substrate kinetic analysis with variable
uridine (3) at pH 7.5. (c) Single-substrate kinetic analysis with variable
5′-amino-5′-deoxyuridine (2) at pH 9.0. (d) Single-substrate kinetic analysis with
variable 5′-amino-5′-deoxyuridine (2) at pH 7.5. A260, absorbance at 260 nm.

2.4. Results: LipM Characterization

2.4.1. In vitro characterization of LipM activity

Since the kinetic analysis revealed both 5′-amino-5′-deoxyuridine (2) and uridine (3)
are good substrates for LipP, while uridine-5′-aldehyde (1) is not, we eliminated one
potential biosynthetic pathway leaving three potential pathways (Fig 2.12). The
downstream enzyme LipM was characterized next to further define the pathway (Fig
2.12). Bioinformatics analysis of LipM revealed sequence similarity to proteins
annotated as putative nucleotidylyltransferases. The potential reaction catalyzed by
46

LipM is shown in Fig 2.13. To interrogate the activity in detail, lipM was expressed in
E. coli, however the recombinant protein was insoluble using a variety of growth and
induction conditions. Therefore, we turned to S. lividans TK64 as a host, which
resulted in the successful preparation of soluble, recombinant LipM (Fig 2.14 a).

Figure 2.12. Proposed biosynthetic pathway for the incorporation of the
aminoribosyl moiety of A-90289.

Figure 2.13. Reaction catalyzed by LipM including in situ generation of the substrate
and amine derivatization with o-phthalaldehyde (OPA).
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The

activity

of

LipM

was

tested

with

α-D-ribose-1-phosphate

or

5-amino-5-deoxy-α-D-ribose-1-phosphate (5) generated in situ by LipP, and analysis
of these reactions revealed a new peak was formed only in the presence of
5-amino-5-deoxy-α-D-ribose-1-phosphate (5) and UTP or - to a lesser extent - TTP,
CTP, or GTP (Fig 2.14 b and Fig 2.15). Unexpectedly, the new peak derived from
activity tests with 5-amino-5-deoxy-α-D-ribose-1-phosphate (5) and the different
NTPs had the same retention time and UV/Vis spectrum as the respective nucleotide
monophosphate (NMP), and co-injections with authentic material and LC-MS
revealed this to be the case.
(a)

(b)

VI
His6-LipM

V
IV

III
II
I

Figure 2.14. Characterization of LipM. (a) SDS-PAGE analysis of purified His6-LipM
(expected MW of 31.3 kD). (b) HPLC analysis starting with 5′-amino-5′-deoxyuridine
(2) or uridine (3). (I) authentic UTP, (II) 3 hr reaction with substrate uridine (3), with
LipP, (III) 3 hr reaction with substrate uridine (3), with LipP and LipM, (IV) 3 hr
reaction with substrate 5′-amino-5′-deoxyuridine (2), with LipP, (V) 3 hr reaction with
substrate 5′-amino-5′-deoxyuridine (2), with LipP and LipM, and (VI) authentic UMP.
A260, absorbance at 260 nm.
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(a)

(b)

(c)

Figure 2.15. In vitro characterization of LipM with alternative NTPs. (a) HPLC
analysis after (I) 3 hr without LipP, (II) 3 hr reaction, and (III) authentic TMP. (b) HPLC
analysis after (I) 3 hr without LipP, (II) 3 hr reaction, and (III) authentic CMP. (c)
HPLC analysis after (I) 3 hr without LipP, (II) 3 hr reaction, and (III) authentic GMP.
A260, absorbance at 260 nm.
2.4.2. In vitro characterization of OPA modified 5′-amino-5′-deoxyuridine (2)
catalyzed by LipM

We hypothesized that the NMP was generated by the degradation of the product via
intramolecular attack of the 2-hydroxy group of the aminoribosyl unit on the proximal
phosphate, a phenomenon that was previously observed upon characterization of
apiofuranosyl-1,2-cyclic phosphate as the product of the plant bifunctional
UDP-apiose/UDP-xylose synthase that catalyzes decarboxylation of UDP-glucuronic
acid[97]. To detect any potential amine-containing product, the reaction components
were first modified with OPA prior to injection, and two new peaks were identified by
HPLC (Fig 2.16).
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Figure 2.16. OPA-modified substrate reaction catalyzed by HPLC.HPLC analysis of
reaction mixtures with OPA derivatization starting with 5′-amino-5′-deoxyuridine (2)
after (I) 30 min without LipP, (II) 30 min without LipM (II), 30 min reaction (III), and 3
hr reaction (IV). A335, absorbance at 335 nm.
The

first

peak

was

identified

as

residual

OPA-modified

5-amino-5-deoxy-α-D-ribose-1-phosphate (OPA-5), while LC-MS analysis of the
remaining peak yielded an (M - H)- ion at m/z = 385.6, consistent with the molecular
formula

C15H18NO7PS

of

an

OPA-modified

5-amino-5-deoxy-α-D-ribose-1,2-cyclicphosphate (OPA-6) (expected m/z = 386.1)
(Fig 2.13and Fig 2.17 a,b). Large-scale purification of OPA-6 and subsequent
LC-MS and 1D and 2D NMR spectroscopic

characterization (Fig 2.15

c,d-2.21)—notably the 1H-31P HMBC data that was consistent with the very recently
discovered metabolite α-D-ribose-1,2-cyclicphosphate[98] (Fig 2.22)—revealed the
expected degradation product (an isoindol-1-one) for OPA-6[99]. Although the
genuine identity of the product of the LipM-catalyzed reaction remained elusive at
this stage, the results did reveal that LipM only utilizes a sugar-1-phosphate
containing a primary amine functionality.
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(a)

(c)

(b)

(d)

Figure 2.17. LC-MS analysis of the OPA-modified LipM product. (a) LC analysis of
the LipM product prior to purification. (b) Mass spectrum for the peak at elution time t
= 11.4 min displaying the expected isotopic distribution (inset). (c) LC-MS analysis of
the LipM product following purification using total negative ion current for detection. (d)
Mass spectrum for the peak eluting at time t = 9.6 min. A335, absorbance at 335 nm.
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(a)

(b)

(c)

Figure 2.18. Characterization of 5′-isoindolinine-5′-deoxy-α-D-ribose-1′,2′-cyclic
phosphate by 1D NMR. (a) 1H-NMR spectrum. (b) 13C-NMR spectrum. (c) 31P-NMR
spectrum. *Acetic acid
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Figure2.19. gCOSY NMR spectrum of 5′-isoindolinine-5′-deoxy-α-D-ribose-1′,2′cyclicphosphate.
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Figure 2.20. gHSQCNMR spectrum of 5′-isoindolinine-5′-deoxy-α-D-ribose-1′,2′cyclicphosphate.
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Figure 2.21.1H-13C gHMBC NMR spectrum of5′-isoindolinine-5′-deoxy-α-D-ribose1′,2′- cyclicphosphate.
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Figure 2.22.1H-31P HMBC NMR spectrum of 5′-isoindolinine-5′-deoxy-α-D-ribose1′,2′- cyclicphosphate
2.4.3. In vitro characterization of substrate 5′-amino-2′,5′-dideoxyuridine (7)
catalyzed by LipM

We rationalized that a stable LipM product would be attainable by using a
2-deoxyribose-containing surrogate substrate. EcUdp as well as other UDPs are
known to catalyze phosphorolysis using thymidine (12) or 2′-deoxyuridine
(11)[96,100], and similarly LipP catalyzed the reaction with either substrate (Fig 2.24
a,b), although the latter was determined to be nearly 35-fold more efficient (Table 3
and Fig 2.23 c,d). Identical to the results utilizing 5′-hydroxy nucleosides (i.e. uridine
3), in situ generation of 2-deoxy-α-D-ribose-1-phosphate did not yield a product when
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tested with LipM. Subsequently, the potential substrate 5′-amino-2′,5′-dideoxyuridine
(7) was synthesized from 2′-deoxyuridine (11), and the reaction catalyzed by LipM
was tested in Fig 2.24 a. HPLC analysis with this surrogate substrate revealed it was
processed by both LipP and LipM, generating two new peaks with uridine (3)-like
chromophores (UVmax~260 nm) (Fig 2.24 b). While the minor peak was identified as
UDP, the major peak did not co-elute with any known uracil (4)-containing metabolite.
LC-MS analysis of the purified new peak revealed an (M - H)- ion at m/z = 517.6,
consistent

with

the

molecular

C14H23N3O14P2

formula

of

UDP-5″-amino-2″,5″-dideoxyribose (8) (expected m/z = 518.1) (Fig2.25). NMR
analysis, including 1H-,

13

C-, and

31

P-NMR, 1H-1H COSY, and 1H-13C HMBC (Figs

2.26-28), confirmed the identity of the product as UDP-5″-amino-2″,5″-dideoxyribose
(8),

thus

consistent

with

the

function

of

LipM

as

a

UTP:5-amino-5-deoxy-α-D-ribose-1-phosphate uridylyltransferase.
O

(a)
O

O

NH
NH

N
H

(b)

O

HO

N

NH

4

O

O

O

HO

N

O

HO
HO

(c)

(d)

Figure 2.23. HPLC and Kinetic analysis of LipP with 2′-deoxynucleosides.(a) HPLC
analysis using thymidine (12)after (I) 3 hr without LipP and (II) 3 hr reaction. (b)
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HPLC analysis using 2′-deoxyuridine (11)after (I) 3 hr without LipP and (II) 3 hr
reaction. (c) Single-substrate kinetic analysis with variable thymidine (12) at pH 9.0.
(d) Single-substrate kinetic analysis with variable 2′-deoxyuridine (11) at pH 9.0. A260,
absorbance at 260 nm.

Figure 2.24. Characterization of LipM with substrate 5′-amino-2′,5′-dideoxyuridine(7).
(a) Enzymatic preparation of the substrate using LipP and the dideoxyuridine
analogue 5′-amino-2′,5′-dideoxyuridine(7) and the reaction catalyzed by LipM to
generate UDP-5″-amino-2″,5″-dideoxyribose (8). (b) HPLC analysis of the reaction
starting with 5′-amino-2′,5′-dideoxyuridine(7) after (I) 3 hr without UTP and LipP, (II) 3
hr without LipM, (III) 1 hr reaction, (IV) 3 hr reaction, and (V) authentic UDP. A260,
absorbance at 260 nm.
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Figure 2.25. LC-MS of the LipM product UDP-5″-amino-2″,5″-dideoxyribose (8)
generated from surrogate substrate 5′-amino-2′,5′-dideoxyuridine(7). (a) LC analysis
of UDP-5″-amino-2″,5″-dideoxyribose (8) following purification. (b) Negative ion
mass spectrum for the peak at elution time t = 3.3 min. (c) Positive ion mass
spectrum for the peak at elution time t = 3.3 min. A260, absorbance at 260 nm.
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(a)

(b)

(c)

Figure 2.26. Characterization of UDP-5″-amino-2″,5″-dideoxyribose (8)by 1D NMR.
(a) 1H-NMR spectrum. (b) 13C-NMR spectrum. (c) 31P-NMR spectrum. *Et3N
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Figure 2.27. gCOSY NMR spectrum of UDP-5″-amino-2″,5″-dideoxyribose (8).
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Figure 2.28. gHSQC NMR spectrum of UDP-5″-amino-2″,5″-dideoxyribose (8).
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2.5. Results: LipO Characterization

2.5.1. In vitro characterization of LipO wild-type and mutant protein

Figure 2.29. Proposed biosynthetic pathway for the incorporation of the
aminoribosyl moiety of A-90289.

After confirming that LipM only utilized the amine-containing ribose-1-phosphate to
produce the activated UDP sugar, a second hypothetical pathway was eliminated
(Fig 2.29). Thus, there were only two pathways left. To differentiate between thses
two, we next turned our attention to the remaining enzyme, LipO. LipO has modest
sequence

similarity

pyridoxal-phosphate

to

several

proteins

(PLP)-dependent

predicted

aspartate

to

belong

aminotransferase

to
(Type

the
I)

superfamily [101][102]. Of note is the sequence similarity of LipO to PacE (37 %
identity / 51 % similarity) involved in the biosynthesis of the pacidamycin family of
antibiotics. The pacidamycins consist of an enamide-containing nucleoside with a
5′-amine functionality as the sole ribose-derived unit, which we and others have
previously speculated proceeds through uridine-5′-aldehyde (1) as an intermediate
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[88,103,104,105] (Fig2.30), which would necessitate transamination at the
nucleoside level to yield the nucleoside building block. Thus, we envisioned an
analogous biosynthetic pathway such that LipO catalyzes aminotransfer utilizing the
corresponding nucleoside uridine-5′-aldehyde (1).

Figure 2.30. Putative biosynthesis of enamide-containing nucleoside antibiotics.
Putative pathway and intermediates leading to the enamide-containing nucleoside
moiety found in pacidamycins.

Similarly to LipM, the gene product of lipO was only soluble when expressed in S.
lividans TK64 (Fig 2.31 a) and was shown by UV/Vis spectroscopy to co-purify with
the cofactor PLP (Fig 2.31 b). The mutant LipO(K282A), expected to be unable to
form an internal aldimine with Lys and hence be inactive, was also produced in S.
lividans TK64 to yield a purified protein devoid of bound PLP (Fig 2.31 a,b).
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(a)

(b)

Figure 2.31LipO wild-type and mutant protein expression and UV/Vis spectrum
analysis. (a) SDS-PAGE analysis of purified His6-LipO (lane 1) and His6-LipO
(K282A) (lane 2, expected MW of 50.7 kD). Several attempts to purify the wild-type
enzyme yielded the same contaminating protein band, which is currently under
investigation to resolve this issue. (b) UV/Vis spectrum of LipO (wild-type) and
LipO(K282A) (mutant).

2.5.2. LipO activity analyzed by HPLC and conversion efficiency with different
amino donors

The activity of LipO was next monitored by HPLC using diode array for detection,
and to simplify the analysis, the putative product 5′-amino-5′-deoxyuridine (2) was
synthesized and used as a standard. When LipO was incubated with
uridine-5′-aldehyde (1) and L-glutamate or L-aspartate, two common amine donors
for the Type 1 aminotransferase superfamily, a small peak representing < 1 %
conversion

appeared

in

both

5′-amino-5′-deoxyuridine

(2)

by

cases,

LC-MS

which

and

was

co-injections

confirmed
with

as

authentic

5′-amino-5′-deoxyuridine (2) (Fig 2.32 a); in contrast, no new peak was observed
with LipO (K282A) (Fig 2.32 b). Further analysis revealed several potential amine
donors

were

substrates—findings

similar

to

many

other

characterized

aminotransferases [102], however, the highest specific activity was obtained with
L-methionine

followed by N-acetylcysteine, L-arginine, and S-adenosyl-L-methionine

(Table 4). Finally, the reverse reaction of LipO using 5′-amino-5′-deoxyuridine (2)
and 4-methylthio-2-oxobutanoate or other amine acceptors as substrates was not
observed, suggesting that the equilibrium of aminotransfer favors formation of
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5′-amino-5′-deoxyuridine (2). The results are consistent with the functional
assignment of LipO as a methionine: uridine-5′-aldehyde (1) aminotransferase and,
importantly, that 5′-amino-5′-deoxyuridine (2) is the likely intermediate in the
biosynthesis of the aminoribosyl moiety of A-90289.

(a)

(b)

Figure 2.32. HPLC characterization of LipO. (a) HPLC analysis starting with
uridine-5′-aldehyde (1) after (I) 4 hr without LipO, (II) 4 hr reaction with glutamate as
an amine donor, (III) 4 hr reaction with L-methionine as an amine donor, (IV) 4 hr
reaction with L-methionine as an amine donor spiked with authentic
5′-amino-5′-deoxyuridine (2), and (V) authentic 5′-amino-5′-deoxyuridine (2). (b)
HPLC analysis of 4 hr reaction with (I) wild-type LipO and (II) LipO(K282A). A260,
absorbance at 260 nm.
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Table 4. Amino donor substrates for LipO.

Amino Donor
L-methionine
N-acetyl- L-cysteine
L -arginine
S-adenosyl- L-methionine
L-ornithine
L-isoleucine methylester
L-histidine
O-phospho- L-serine
L-glutamine
L-proline
L-asparagine
L-phenylalanine
L-lysine
L-histidine
DL-alanine
L-cysteine
S-adenosyl- L-homocysteine
glycine
L-tyrosine
L-isoleucine
L-serine
L-threonine
L-valine
L-serine
L-glutamate
DL-isoleucine
L-tryptophan
β-alanine
D-cysteine
D-alanine
NH4OH
L-aspartate

Relative
Specific
Activitya
100
58
58
55
50
47
47
47
44
44
21
19
16
13
13
11
9.4
7.1
7.1
5.0
5.0
3.8
3.5
2.9
2.3
1.8
1.5
1.5
1.2
0.9
0.9
0.6

The specific activity of LipP with L-methionine is 0.12 μmol min-1 mg-1 at 30 °C and
pH = 7.5, which is comparable to the specific activity of methionine-glyoxylate
transaminase from Brassica sp [106].
a
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2.6. Results: LipN Characterization

2.6.1.In vitro characterization of LipN activity

Figure 2.33. Proposed biosynthetic pathway for the incorporation of the
aminoribosyl moiety of A-90289.

After the activity of LipO was confirmed, the biosynthetic pathway for the
aminoribose was revealed to start with UMP with sequential catalysis by LipL, LipO,
LipP and LipM. We finally turned our attention to LipN, which has low sequence
identity to a small number of proteins annotated as putative glycosyltransferases.
We hypothesized that LipN utilized UDP-5″-amino-2″,5″-dideoxyribose (8) as a sugar
donor. Once again, soluble protein was only obtained upon heterologous expression
in S. lividans TK64 (Fig 2.34 a). Unfortunately UDP-5″-amino-2″,5″-dideoxyribose (8)
was not stable upon storage, in this case degrading to UDP and an undetermined
product likely by hydrolysis of the anomeric bond (Fig 2.34 b). Thus we again relied
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on the in situ generation of substrate beginning with 5′-amino-5′-deoxyuridine (2) or
5′-amino-2′,5′-dideoxyuridine(7). While no glycosyltransferase activity was observed
with PRPP or ribose-1-phosphates generated with LipP, HPLC analysis of LipN
reactions using surrogate acceptor uridine (3) revealed a new, small peak starting
from either 5′-amino-5′-deoxyuridine (2)(Fig 2.35) or 5′-amino-2′,5′-dideoxyuridine(7)
(Fig 2.36) as the ultimate sugar donor generated from LipP and LipM. Our pilot
experiments suggested higher yields were obtained with the genuine sugar donor
UDP-5-amino-5-deoxy-α-D-ribose, and thus no further experiments were undertaken
with UDP-5″-amino-2″,5″-dideoxyribose (8). Following large-scale purification of the
LipN - product generated from 5′-amino-5′-deoxyuridine (2) and uridine (3), mass
and complete NMR spectroscopic analysis (Fig 2.37-40)—notably the 1H-13C HMBC
demonstrating the H-1′′and C-5′ correlation (Fig 2.41)—revealed the identity of the
new product as 5′-O-(5′′-amino-5′′-deoxy-α-D-ribose)-uridine (9) (Fig 2.35). Thus, the
function of LipN is assigned as a 5-amino-5-deoxy-α-D-ribosyltransferase that
catalyzes the terminal step in the biosynthesis of the aminoribosyl moiety.
(a)

(b)

Figure 2.34. LipN protein gel and HPLC analysis the degradation of
UDP-5″-amino-2″,5″-dideoxyribose (8).(a) SDS-PAGE of partially purified His6-LipN
(expected MW of 42.3 kD). (b) HPLC analysis using ion-pairing chromatography
revealing the degradation of UDP-5″-amino-2″, 5″-dideoxyribose (8) to UDP following
storage at -20 °C for one week.
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Figure 2.35. In vitro characterization of LipN with substrate 5′-amino-5′-deoxyuridine
(2). (a) Enzymatic preparation of the sugar donor substrate using LipP and LipM, and
the reaction catalyzed by LipN using the surrogate acceptor substrate 3 to generate
5′-O-(5′′-amino-5′′-deoxy-β-D-ribose)-uridine (9). (b) HPLC analysis of the reaction
starting with 5′-amino-5′-deoxyuridine (2) after (I) 3 hr without LipN and (II) 3 hr
reaction. *indicates expected retention time for residual UTP and co-product UDP.
A260, absorbance at 260 nm.
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(a)

(b)

Figure
2.36.
In
vitro
characterization
of
LipN
with
substrate
5′-amino-2′,5′-dideoxyuridine (7). (a) Enzymatic preparation of the sugar donor
substrate using LipP and LipM, and the reaction catalyzed by LipN using the
surrogate acceptor substrate uridine (3) to generate the putative product shown. (b)
HPLC analysis using uridine (3) as the acceptor substrate and UDP-5″-amino-2″,
5″-dideoxyribose (8) as the donor substrate (generated in situ starting from
5′-amino-2′,5′-dideoxyuridine (7) after (I) 3 hr without LipN and (II) 3 hr reaction.
*indicates expected retention time for residual substrate UTP and product UDP. A260,
absorbance at 260 nm.
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(a)

(b)

Figure 2.37. LC-MS of the LipN product 5′-O-(5′′-amino-5′′-deoxy-β-D-ribose)-uridine
(9) starting form 5′-amino-5′-deoxyuridine (2) as the ultimate sugar donor and uridine
(3)
as
a
surrogate
acceptor.
(a)
LC
analysis
of
5′-O-(5′′-amino-5′′-deoxy-β-D-ribose)-uridine (9) following purification. (b) Positive ion
mass spectrum for the peak at elution time t = 3.2 min. A260, absorbance at 260 nm.
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Figure 2.38. Characterization of 5′-O-(5′′-amino-5′′-deoxy-β-D-ribose)-uridine (9) by
1D NMR. (a) 1H-NMR spectrum. (b) 13C-NMR spectrum. *unidentified impurity
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Figure 2.39. gCOSY NMR spectrum of 5′-O-(5′′-amino-5′′-deoxy-β-D-ribose)-uridine
(9).

74

Figure 2.40. gHSQC NMR spectrum of 5′-O-(5′′-amino-5′′-deoxy-β-D-ribose)-uridine
(9).
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Figure 2.41.1H-13C gHMBC NMR spectrum of 5′-O-(5′′-amino-5′′-deoxy-β-D-ribose)uridine (9).
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2.7. Conclusion

In summary, we have completed the functional assignment of five enzymes involved
in the modification and incorporation of the aminoribosyl moiety of A-90289
antibiotics. The pathway is initiated by the LipL-catalyzed conversion of a novel
ribosyl donor UMP to form the aldehyde uridine-5′-aldehyde (1) [88]. Following
introduction of the amine by LipO, LipP catalyzes phosphorolysis to initiate “salvage”
of the modified sugar and LipM subsequently catalyzes the formation of an activated
pentofuranose that serves as the final sugar donor. Finally, the ribosyltransferase
LipN completes the pathway by incorporation of the aminoribosyl moiety, the identity
of which is apparently dictated by the specificity of the pathway-initiating enzyme
LipL and the penultimate enzyme LipM. The end result is a sugar biosynthetic
pathway highlighted in Fig 2.42 that not only establishes an alternative mechanism
for ribosylation but also features intriguing variations of the established paradigm for
glycosylation.

Threonine

Figure 2.42. Finalized biosynthetic pathway for the incorporation of the aminoribosyl
moiety of A-90289.

2.8. Discussion

Bacterial natural products are notorious for their diverse array of sugar modifications
that are typically critical for their biological activity. As a result there has been a
significant effort toward understanding the molecular details behind incorporation of
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these sugars, in part with the expectation that the results will ultimately enable
rationale manipulation of sugar biosynthetic pathways as a strategy to produce novel
glycosylated

compounds

[63,64].

Undoubtedly,

the

identification

and

characterization of new pathways will afford more tools for applying such a structural
diversification approach, and thus we initiated studies toward delineating the
biosynthetic mechanism of a unique pentofuranose—an aminoribosyl moiety found
in several lipopeptidyl nucleosides of potential therapeutic significance as antibiotics.
Our strategy to unravel the pathway was to reconstitute the enzyme activities in vitro,
which ultimately required the use of the heterologous host S. lividans TK64 to obtain
three of the four enzymes in soluble form. Our prior results with LipL demonstrated
this enzyme had strict specificity for the substrate UMP to initiate the pathway [88],
an attribute that was not reciprocated by the four enzymes assigned in this study.
LipO utilized a variety of amine donors with L-methionine as the slightly preferred
amine source, the biological relevance of which is currently under investigation.
Likewise, the phosphorylase LipP was equally efficient with hypothetical pathway
intermediates 5′-amino-5′-deoxyuridine (2) and uridine (3). Sequence analysis of the
whole genomes of the Actinomycetales has revealed minimally one 5′-nucleosidase
is encoded within the chromosomal DNA suggesting these organisms have the
capability to convert the nucleic acid building block UMP to uridine (3). Thus, based
solely on the results with LipP, the identity of the in vivo substrate could not be
established. However, the realization that the amine needs to be incorporated prior
to formation of activated sugar would necessitate an additional, unidentified enzyme
to oxidize α-D-ribose-1-phosphate prior to LipO catalysis if uridine (3) was indeed the
pathway precursor. Thus, we currently prefer a pathway originating from UMP
without the involvement of uridine (3) as shown in Figure 2.42.

While we were initially disheartened by the lack of substrate specificity of LipP, this
low specificity turned out to be critical for discovering the function of LipM by
enabling the preparation of a surrogate substrate that was converted to a less
unstable product for structural elucidation. Similarly, we took advantage of the
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promiscuity of LipN with respect to the sugar acceptor to define its function as a
ribosyltransferase.

Interestingly,

although

the

genuine

sugar

donor

UDP-5-amino-5-deoxy-α-D-ribosewas initially only indirectly identified as the LipM
-product

based

on

the

identification

of

UMP

and

OPA

modified

5-amino-5-deoxy-α-D-ribose-1,2-cyclicphosphate (OPA-6) and—despite exhaustive
attempts—could not be directly observed by MS, our successful analysis of LipN
with in situ generated UDP-5-amino-5-deoxy-α-D-ribose suggests that this activated
sugar is formed yet is refractive to direct characterization using the conditions
employed

here.

Although

it

remains

a

possibility

that

5-amino-5-deoxy-α-D-ribose-1,2-cyclicphosphate (6) is generated enzymatically by a
contaminating protein, several activated sugars are known to be unstable; for
instance,

it

has

recently

been

reported

that

the

expected

product

of

UDP-apiose/UDP-xylose synthase can be transiently detected by high-field NMR
prior to degrading to the isolable apiofuranosyl-1,2-cyclic phosphate [97] and the
activated carbocycle NDP-valienol can only be detected by MS within the crude
reaction mixture [107].

Although the glycosylation process predominantly involves the incorporation of
hexoses, it is not limited to these sugars: several pentose units, for example, are
derived

from

this

glycosylation

mechanism

that

typically

proceeds

with

decarboxylation of an NDP-glucuronic acid (Fig 2.43) [97,108,109,110,111,112].
Alternatively, sugar salvage pathways from plants [113,114][115], and the
thermophilic bacterium Thermus caldophilus GK24 [116] have been characterized
that utilize broad-specificity nucleotidylyltransferases capable of activating the
pentopyranosyl phosphates of D-xylose and L-arabinose albeit with lower efficiencies
than the α-D-hexopyranosyl phosphates of glucose and galactose. Furthermore, a
nucleotidylyltransferase from Salmonella enterica typhimurium LT2 (Ep) has been
extensively studied and shown to utilizeα-D-xylose-1-phosphate along with dozens of
α-D-hexopyranosyl phosphates [117,118,119]. Although a more in depth investigation
is

underway,

our

results

identified
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LipM

as

an

unusual

α-D-pentofuranosyl-1-phosphate-activating enzyme with an apparently more refined
specificity and hence well-defined role in A-90289 biosynthesis. Furthermore, LipM
was shown to have an absolute requirement for the primary amine functionality,
which is likewise unusual relative to other bacterial nucleotidylyltransferases that
have been demonstrated to activate unnatural aminohexoses although with equal or
less efficiency relative to the hydroxylated counterpart [118,119,120,121,122].

Figure 2.43. The conventional glycosylation mechanism with an NDP-sugar as the
sugar donor.

Copyright © Xiuling Chi 2013
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Chapter three: Biosynthetic pathway of 2′-deoxyaminoribosyl moiety of
muraminomicin

3.1. Background

Muraminomicin, which is isolated from Streptosporangium amethystogenes SANK
60709, was discovered based on its potent inhibitory activity on bacterial translocase I
(IC50=12.8 ng/ml)[84]. Subsequently, muraminomicin was shown to have excellent anti
Gram-positive bacteria activity against strains like S. aureus & B. subtilis
[123].Structural determination revealed muraminomicin belonged to the peptidyl
nucleoside antibiotics family (Fig 3.1). However, unlike A-90289 and caprazamycins,
a few unique structural features were uncovered. These included a deoxyheptose in
place of the permethylated rhamnose, an appended succinyl moiety, and the
incorporation of 2-deoxyribosyl. The structure-activity relationship of muraminomicin
is still not defined, and nothing is known about how this molecule is assembled. In
order to pinpoint the factors controlling the incorporation of these and other structural
variations

observed

in

muraminomicin,

the

biosynthetic

gene

cluster

of

muraminomicin has been identified and five 2-deoxyfuranoses biosynthetic related
enzymes (Mra20-Mra24) were uncovered, all with sequence similarity to those
identified within the A-90289 gene cluster. Thus, it appeared that the 2-deoxyribose
followed the unusual paradigm revealed from analysis of the A-90289 biosynthetic
pathway.
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Figure 3.1. Structures of representative lipopeptidyl nucleoside antibiotics containing
an aminoribofuranoside appendage (blue).

Significantly natural product with a similar 2-deoxyfuranose structure are rare, and
thus by unraveling the biochemical events in muraminomicin biosynthesis is expected
to provide us novel and valuable information that can be used to prepare new
compounds. We have now successfully defined the function of the two of the enzymes
to provide insight into how this deoxy furanose is assembled de novo.
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3.2. Materials and methods

3.2.1. Chemicals and instrumentation

Nucleoside bases, nucleosides, and nucleotides were purchased from Sigma or
Promega. Buffers, salts, and media components were purchased from Fisher
Scientific. UV/Vis spectroscopy was performed with a Bio-Tek µQuant microplate
reader

using

Microtest™

96-well

plates

or

a

Shimadzu

UV/Vis-1800

Spectrophotometer. Synthetic oligonucleotides were purchased from Integrated DNA
Technologies. DNA sequencing was performed using the BigDye™Terminator
version 3.1 Cycle Sequencing kit from Applied Biosystems, Inc. and analyzed at the
University of Kentucky Advanced Genetic Technologies Center. HPLC was
performed with a Waters Alliance 2695 separation module (Milford, MA) equipped
with a Waters 2998 diode array detector and an analytical Apollo C-18 column (250
mm x 4.6 mm, 5 μm) or a semi-preparative Apollo C-18 column (250 mm x 10 mm, 5
μm) purchased from Grace. Electrospray ionization-MS was performed using an
Agilent 6120 Quadrupole MSD mass spectrometer equipped with an Agilent 1200
Series Quaternary LC system and an Eclipse XDB-C18 column (150mm x 4.6 mm, 5
μm, 80Å). NMR data were collected using a Varian Unity Inova 300, 400 or 500 MHz
Spectrometer.

3.2.2. Synthesis of substrates

The synthesis of 5′-amino-5′-deoxyuridine (2) and 5′-amino-2′,5′-dideoxyuridine (7)
was described in section 2.2.5 and 2.2.6 [124]. The identical two-step procedure for
the latter was used to synthesize 5′-amino-5′-deoxythymidine (10) (see below).
Step 1: 5′-Azido-5′-deoxythymidine.1H-NMR (500MHz, D2O): δ 7.55 (s, 1H), 6.27 (t,
1H, J = 7 Hz), 4.51-4.45 (m, 1H), 4.08-4.04 (m, 1H), 3.72-3.51 (m, 2H), 2.50-2.31 (m,
2H), 1.89-1.82 (s, 3H);

C-NMR (100MHz, D2O): δ 166.2 (C), 151.4 (C), 136.97

13

(CH), 111.2 (CH), 84.8 (CH), 84.1 (CH), 70.5 (CH), 51.2 (CH2), 37.4 (CH2), 11.2
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(CH3).
O
NH

3
1

5

5'

N

O

N3
H

4'

O

1'
2'

HO

ppm

Step 2: 5′-Amino-5′-deoxythymidine, 2.1H-NMR (500 MHz, D2O): δ 7.36 (s, 1H), 6.07
(t, 1H, J = 7 Hz), 4.38-4.30 (m, 1H), 4.08-3.95 (m, 1H), 3.35-3.08 (m, 2H), 2.45-2.22
(m, 2H), 1.78-1.70 (s, 3H);

C-NMR (125 MHz, D2O): δ 166.1 (C), 151.3 (C), 138.3

13

(CH), 111.2 (CH), 86.5 (CH), 81.6 (CH), 71.2 (CH), 41.0 (CH2), 37.3 (CH2), 11.3
(CH3). (×: acetate)
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O
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3.2.3. Cloning of the muraminomicin gene cluster

Streptosporangium amethystogenes sp. SANK 60709genomic DNA was partially
digested with Sau3AI to give ~40-kb DNA fragments that were dephosphorylated with
bacterial alkaline phosphatase (BAP) and ligated into BamHI-digested cosmid vector
SuperCos1-P that contains the loxP site in SuperCos1 and was dephosphorylated by
BAP after XbaI digestion. The ligation products were packaged with Gigapack III Gold
packaging extract as described by the manufacturer, and the resulting recombinant
phage was used to transfect E. coli XL-1 Blue MR. Approximately 10,000 colonies
from the obtained genomic library were screened by colony hybridization using
digoxigenin (DIG)-labeled DNA obtained by PCR using degenerate primers as
previously described[125]. Hybridization was carried out using DIG easy hyb at 42 °C
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and the resulting filter was washed under high stringency conditions (0.1 X SSC
including 0.1 % SDS, 68 °C). Detection was performed using CDP-Star according to
the manufacturer′s procedures.

Based on restriction digest analysis, four positive cosmids, pMra01-04, were isolated
and sequenced using a Roche GS FLX system. Potential open reading frames were
defined using Frameplot 4.0, and database comparison for sequence homology was
performed with BLAST search tools using the National Center for Biotechnology
Information. The sequence has been deposited at GenBank under accession no.
AB746937.

3.2.4. Construction of genomic cosmid libraries

Genomic DNA of muraminomicin was isolated following a standard instruction [126].
Then the genomic DNA was packaged using BigEasy® v2.0 Linear Cloning Kits [127].
Firstly, the genomic DNA was partially digested with NotI to generate restriction
fragments. Then the produced fragments were ligated to the pJAZZ® vector and
transformed into BigEasy TSATM electrocompetent cells. More than 5000 colonies
were obtained as positive clones. Degenerate primers (mra24_probe_for and
mra24_probe_rev) (Table 5) were designed to amplify the internal nucleotide
sequences of dioxygenase from the genomic DNA of Streptosporangium
amethystogenes sp. The amplified fragments were labeled with DIG and preceded
with hybridization and finally used for screening. The colony hybridization and
southern blot analyses revealed four different cosmid clones.

3.2.5. Inactivation of mra20 gene by PCR targeting
The double crossover inactivation experiment was carried out using a modified
PCR-targeting REDIRECT protocol [128]. Briefly, a chloramphenicol resistance gene
with engineered flanking flippase recognition target (FRT) was used as a template to
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amplify disruption cassette using the primer pair (mra20_inact_for, mra20_inact_rev)
(Table 5). E. coli BW25141/pKD78 (ampr) cell was transferred with pMra02 cosmid.
The resulting chloramphenicol inactivation cassettes were then introduced into E. coli
BW25141/pKD78 (ampr) by electroporation. The incubation temperature was
increased from 30°C to 37°C to eliminate the temperature sensitive cosmid, and the
resulting amp and apr resistant colonies were harvested for further use. A control
primer pair (mra20_con_for + mra20_con_rev) was created from nearly upstream of
mra20 and was used to confirm the replacement of the targeted gene with the
chloramphenicol cassette (Table 5). The final mutated cosmid (pMra02-mra20-) was
transformed into E. coli ET12567/pUZ8002 and conjugated into muraminomicin
producing strain following the standard protocol procedure.

3.2.6. Cloning of genes for heterologous expression

Genes were amplified by PCR using Expand Long Template PCR System from
Roche with supplied Buffer 2, 200 μM dNTPs, 5% DMSO, 10 ng DNA pMra02, 5 U
DNA polymerase, and 200 nM each of the following primer pairs (Table 5). The PCR
program included an initial hold at 94 °C for 2 min, followed by 30 cycles of 94 °C for
10 s, 56 °C for 15 s, and 68 °C for 60 s. The gel-purified PCR product was inserted
into pET-30 Xa/LIC using ligation-independent cloning as described in the provided
protocol to yield pET30-mra20 to pET30-mra24 (Table 6). The genes were
sequenced to confirm PCR fidelity.
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Table 5. List of primers used in muraminomicin.

Primers
mra20_for
mra20_rev
mra23_for
mra23_rev
mra21_for
mra21_rev
mra22_for

Oligonucleotide sequence
5′- GGTATTGAGGGTCGCATGAACGAGAT -3′
5′- AGAGGAGAGTTAGAGCCTCACCCGG -3′
5′- GGTATTGAGGGTCGCATGTCGGTCG -3′
5′- AGAGGAGAGTTAGAG CCTCAGCCGA -3′
5′- GGTATTGAGGGTCGCATGAGCGGGA-3′
5′- AGAGGAGAGTTAGAGCCTCATCCGAC-3′
5′- GGTATTGAGGGTCGCATGGCACCCG -3′

mra22_rev
mra24_for

5′- AGAGGAGAGTTAGAGCCTCACTCTGA-3′
5′- GGTATTGAGGGTCGCATGAGCCAATT -3′

mra24_rev
mra20_inact_for

5′- AGAGGAGAGTTAGAGCCTCAAGCGG-3′
5′-CCTGGACGCGCTCGATACGGCGGGAAGGCACGTCGGA
TGATTCCGGGGATCCGT CGACC-3′
5′-CTCTGTTACCGGCGGGAAGACGCCGCCAACGGGTGTTC
A TGTAGGCTGGAGCTGCTTC-3′
5′-GCCGGCGTCGCCGACGT-3′
5′-TTCACGCGCGGATTACG-3′
5′-GAACGGCACACAGACCGAAC-3′
5′-ATCTTGTCGCAGACGCCGAG-3′

mra20_inact_rev
mra20_con_for
mra20_con_rev
mra24_probe_for
mra24_probe_rev

Plasmids were introduced into E. coli BL 21(DE3) cells, and the transformed strains
were grown in LB supplemented with 50 μg/mL kanamycin. Following inoculation of
500 mL of LB with 50 μg/mL kanamycin, the cultures were grown at 18°C until the
cell density reached an OD600 ~ 0.5 when expression was induced with 0.1 mM IPTG.
Cells were harvested after an overnight incubation at 18 °C and lysed using a French
Press with one pass at 15000 psi. Following centrifugation the protein was purified
using affinity chromatography with Ni-NTA agarose from Qiagen, and the
recombinant proteins were desalted into 50 mM Tris-HCl (pH 8), 100 mM NaCl, and
5 % glycerol using a PD-10 desalting column. The purified protein was concentrated
using an Amicon Ultra 10000 MWCO centrifugal filter and stored as glycerol stocks
(40%) at -20 °C. Protein purity was assessed as by 12% acrylamide SDS-PAGE;
His6-tagged proteins were utilized without further modifications.
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Table 6. List of plasmids constructed/used in muraminomicin.

Strain/Plasmid
E.coli Nova-Blue
E.coli BL21 (DE3)
pET30
pET30- mra20
pET30- mra23
pET30- mra21
pET30- mra22
pET30- mra24
pUWL201pw
pUWL201pw- mra21
pUWL201pw- mra22
pUWL201pw-mra24

Characteristics and Relevance
Host for routine cloning works
Host for protein expression
Expression vector
mra20 gene cloned to pET30
mra23 gene cloned to pET30
mra21gene cloned to pET30
mra22 gene cloned to pET30
mra24 gene cloned to pET30
Expression vector
mra21 gene cloned to pUWL201pw
mra22 gene cloned to pUWL201pw
mra24 gene cloned to pUWL201pw

References
Novagen
Novagen
Novagen
This study
This study
This study
This study
This study
This study
This study
This study
This study

3.2.7. In vitro characterization of Mra20

Reactions

consisted

of

25

mM

potassium

phosphate

pH

7.5,

2

mM

5′-amino-5′-deoxyuridine (2) or analogue, and 100 nM Mra20 at 30 °C, and
terminated by the addition of cold TCA to 5% (w/v) or by ultrafiltration using a
Microcon YM-3. Following centrifugation to remove protein, the reaction components
were analyzed by HPLC using a C-18 reverse-phase column. A series of linear
gradients was developed from 40 mM phosphoric acid-triethylamine pH 6.5 (A) to 20%
methanol (B) in the following manner (beginning time and ending time with linear
increase to % B): 0-8 min, 0% B; 8-18 min, 60% B; 18-25 min, 95% B; 25-32 min, 95%
B; and 32-35 min, 0% B. The flow rate was kept constant at 1.0 mL/min, and elution
was monitored at 260 nm.

To determine the kinetic constants with respect to the co-substrate nucleoside,
reactions were carried out in 50 mM Tris-HCl pH 9.0 consisting of saturating
phosphate (1.5 mM) and variable nucleoside (25 – 5,000 μM), and 100 nM Mra20 at
30 °C under initial velocity conditions. The reactions were terminated with 0.1 M
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sodium hydroxide, and nucleobase formation was determined by UV/Vis
spectroscopy with ∆ε300 nm = 3, 700 M-1 at pH 13 for thymine (13) and ∆ε290 nm = 5, 700
M-1 at pH 13 for uracil (4).

3.2.8. In vitro characterization of Mra23

Reactions consisted of 50 mM potassium phosphate pH 7.5, 5 mM MgCl2, 2 mM
thymidine (12) or analogue, 5 mM UTP, 5 μM Mra20, and 1 μM Mra23 at 30 °C, and
the reaction terminated by the addition of cold TCA to 5% (w/v) or by ultrafiltration
using a Microcon YM-3. The activity of Mra23 was tested with sugar-1-phosphates
generated in situ from synthetic 5′-amino-2′,5′-dideoxyuridine(7), thymidine (12),
5′-amino-5′-deoxythymidine (10)or 2′-deoxyuridine (11) with co-substrate UTP.
Following centrifugation to remove protein, the reaction components were analyzed
by HPLC using a phosphoric acid-triethylamine mobile phase as described above.
LC-MS was performed using a linear gradient from 0.1% formic acid in water to 0.1%
formic acid in acetonitrile over 20 min. The flow rate was kept constant at 0.4 mL/min,
and elution was monitored at 254 nm.

3.2.9. Subcloning and expression in S. lividans TK-64

Plasmids pET30-mra21, pET30-mra22 and pET30-mura24 were digested with
NdeI-HindIII and the DNA fragment of the expected size was purified and ligated to
the identical sites of pUWL201pw to yield pUWL201pw-mra21, pUWL201pw-mra22
and pUWL201pw-mra24, respectively (Table 6). The detailed procedures were
described insection 2.2.8.

3.2.10. In vitro characterization of Mra21

Reactions

consisted

of

50

mM

potassium

90

phosphate

pH

7.5,

2

mM

uridine-5′-aldehyde (1), 2 mM amine donor, 200 μM PLP, and 1 μM Mra21 at 30 °C,
and the reaction terminated by the addition of cold TCA to 5% (w/v) or by
ultrafiltration using a Microcon YM-3. Different amino acids were used as amine
donors to test Mra21 activity. HPLC analysis of the reaction was similar to that
described for LipM.

3.2.11. In vitro characterization of Mra22

Reactions

consisted

of

50

mM

potassium

phosphate

pH

7.5,

2

mM

5′-amino-2′,5′-dideoxyuridine(7) or 5′-amino-5′-deoxythymidine (10), 2.8 μM Mra20 at
30 °C for 2 hours. Mra20 was removed by ultrafiltration, and 86 μL of the filtrate was
added to a solution of 5 mM MgCl2, 2 mM UTP, 1 mM 2′-deoxyuridine (11), 12 μM
Mra23, and 7 μM Mra22 (final volume of 100 mL) and incubated at 30 °C for the
indicated time points. HPLC analysis was performed using a TFA mobile phase as
described above.

3.2.12. In vitrocharacterization of Mra24

Reactions consisted of 50 mM Tris-HCl (pH 7.5), 0.5 mM UMP or 2′-deoxy UMP, 1
mM α-KG, 0.2 mM ascorbate, 0.1 mM FeCl2, and 3 μM Mra24at 30 °C. Control
reactions were performed with or without the addition of corresponding components
or enzyme. The reaction terminated by the addition of cold TCA to 5% (w/v) or by
ultrafiltration using a Microcon YM-3. HPLC analysis of the reaction was similar to
that described for LipM.

3.3. Results: Identification of muraminomicin gene cluster

The structural similarity to liposidomycin, caprazamycin, and A-90289 suggested the
muraminomicin gene cluster shares most of the biosynthetic genes. We recently
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reported the utility of using degenerate primers for a gene annotated as aserine
hydroxymethyltransferase (described in section 2.1) to specifically identify the genetic
locus involved in the biosynthesis of these related nucleosides, and this strategy was
employed here to amplify DNA fragments with the expected size from
Streptosporangium amethystogenes sp. SANK 60709 genomic DNA. The amplified
DNA was utilized as a probe to ultimately identify 4 cosmids (pMra01-04) that were
sequenced and analyzed, yielding 53 complete orfs within 73.6 kb of contiguous DNA
(Fig 3.2a and Table 7). Of these orfs, 22 were shared amongst all of the
aforementioned clusters and a minimum of 2 orfs were unique to the muraminomicin
gene cluster: mra3 encoding a hypothetical membrane protein and mra3 encoding a
putative C-methyltransferase of the radical SAM superfamily and mra4 encoding a
hypothetical membrane protein. These orfs are inserted within a subcluster of genes
responsible for the biosynthesis of the permethylated rhamnose, and the gene
encoding a 3′-O-methyltransferase involved in A-90289 and caprazamycin
biosynthesis (Fig3.2b) is missing from the muraminomicin gene cluster. Thus, it is
proposed that Mra3 catalyzes C-methylation at C-6 of rhamnose to generate the
unusual

heptose

found

in

muraminomicin

3-O-succinyltransferase (Fig3.1).
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while

Mra4

functions

as

a

Figure 3.2. Genetic architecture of the muraminomicin gene cluster. (a) Organization
of the ~74-kb of sequenced DNA. (b) Comparison of the subcluster of genes involved
in the biosynthesis of the rhamnosyl moiety. (c) Comparison of the subcluster of
genes involved in the biosynthesis of the aminoribosyl moiety.
Table 7. Annotation of ORFs within the muraminomicin gene cluster.
Protein
a

Sequence similarity (protein,

Size
b

Identity /

Proposed function
polymerase,sigma

accession no., origin)

similarity

SrosDRAFT_47470

93/97

ORF-1

25

RNA

ORF-1

12

anti-anti-sigma factor

SrosDRAFT_47460

89/94

ORF-1

35

hypothetical protein

SghaA1_010100033943

62/72

ORF-1

23

response regulator

SrosDRAFT_47450

89/94

ORF-1

56

PAS domain S-box protein

SrosDRAFT_47440

89/95

ORF-1

39

glycosyltransferase

SrosDRAFT_47420

83/92

ORF-1

32

hypothetical protein

SrosDRAFT_47400

74/82

ORF-9

24

hypothetical protein

FRAAL6120 (YP_716259)

49/65

ORF-8

36

sugar

SrosDRAFT_47390

79/84

ORF-7

30

L-proline dehydrogenase

SrosDRAFT_47380

83/89

diacid

utilization
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A-90289
c

d

Identity %

Table 7 (continued)
ORF-6

56

delta-1-pyrroline-5-carbox

SrosDRAFT_47370 (ZP_04474156)

92/95

ORF-5

18

hypothetical protein

SrosDRAFT_40310 (ZP_04473452)

84/90

ORF-4

15

DNA-binding protein

SrosDRAFT_40320 (ZP_04473453)

70/79

ORF-3

29

hypothetical protein

SGR_1524 (YP_001823036)

49/62

ORF-2

30

NmrA family protein

Franean1_1468 (YP_001505814)

65/76

ORF-1

19

tetR-family transcriptional

Franean1_1469 (YP_001505815)

72/80

Mra1

39

rhamnosyltransferase

Cpz31 (ACQ63639)

78/88

LipB1

74

Mra2

39

sugar

Cpz30 (ACQ63638)

78/82

LipA1

74

Mra3

52

radical

CalU22 (AAM94801)

67/81

Mra4

38

predicted

NdasDRAFT_4699 (ZP_04335569)

55/67

Mra5

26

sugar

Cpz29 (ACQ63637)

81/89

LipZ

83

Mra6

21

TmrB-like protein

Cpz27 (ACQ63635)

71/80

LipX

67

Mra7

39

SAM-dependent

Cpz26 (ACQ63634)

74/84

LipW

72

Mra8

32

alcohol dehydrogenase

Cpz25 (ACQ63633)

88/93

LipV

86

Mra9

60

hypothetical protein

Cpz24 (ACQ63632)

69/78

LipU

68

Mra10

34

lipase

Cpz23 (ACQ63631)

78/88

LipT

79

Mra11

12

ABC multidrug resistance

Cpz22 (ACQ63630)

77/84

LipS

76

Mra12

49

acyltransferase

Cpz21 (ACQ63629)

75/85

LipR

76

Mra13

35

acyl-CoA synthase

Cpz20 (ACQ63628)

87/90

LipQ

84

Mra14

4
42

SHMT-like

Cpz14 (ACQ63622)

81/87

LipK

83

Mra15

44

aminotransferase

Cpz13 (ACQ63621)

77/86

LipJ

76

Mra16

18

TmrB-like protein

Cpz12 (ACQ63620)

72/81

LipI

71

Mra17

21

SAM-dependent

Cpz11 (ACQ63619)

75/86

LipH

78

Mra18

17

beta-hydroxylase

Cpz10 (ACQ63618)

84/91

LipG

80

Mra19

32

AraC family transcriptional

Cpz9 (ACQ63617)

65/72

LipF

61

45

pyrimidine-nucleoside

DealDRAFT_0710 (ZP_03728855)
46/63

LipP

42

phosphorylase

Dethiobacter alkaliphilus AHT 1

SAM
membrane

Mra20
5
Mra21

43

aminotransferase

CetH (ACH85568)

52/64

LipO

41

Mra22

36

glycosyltransferase

Orf13 (BAI23321)

39/57

LipN

36

Mra23

23

nucleotidylyltransferase

Amir_3895 (YP_003101615)

40/51

LipM

33

Mra24

21

dioxygenase

Orf7 (BAI23315)

41/56

LipL

40

ORF1

32

DNA

Mpop_3269 (YP_001925955)

29/43

ORF2

61

glucose-methanol-choline

SACE_4301 (YP_001106495)

46/58

ORF3

16

hypothetical protein

N9414_23023 (ZP_01630686)

33/48

polymerase

beta
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Table 7 (continued)
ORF4

19

hypothetical protein

SrosDRAFT_27630 (ZP_04472191)

74/83

ORF5

50

hydrolase

Svir_18520 (YP_003133702)

62/72

ORF6

18

NADPH-dependent

Pat9bDRAFT_2775 (ZP_05729459)

43/65

ORF7

33

amino

Sare_4562 (YP_001539321)

49/62

ORF8

39

acyl-CoA dehydrogenase

TcurDRAFT_15750 (ZP_04030556)

73/84

ORF9

28

hypothetical protein

hyg24 (ABC42561)

43/56

ORF10

30

Short-chain

Bxe_B2739 (YP_552606)

57/71

ORF11

38

hypothetical protein

Plav_2009 (YP_001413280)

63/78

ORF12

14

hypothetical protein

Veis_2934 (YP_997688)

57/73

ORF13

38

acyl-CoA dehydrogenase

TcurDRAFT_39460 (ZP_04032895)

50/65

acid

FMN

adenylation

a

Sequences are deposited at NCBI (accession no. AB746937).bNumbers are in
amino acids.c% sequence identity and similarity for the entire length of the
proteins.dSequences are deposited at NCBI (accession no. AB530986).
In contrast to the obvious differences within the genetic architecture of the locus
involved in the biosynthesis of the rhamnosyl moiety, the five gene subcluster
required for aminoribose formation appeared essentially the same for theA-90289 and
muraminomicin gene clusters (Fig3.2c). However, minimally two differences were
uncovered upon closer bioinformatics analysis: (i) the sequence identity between
LipP-L and Mra20-24 were considerably lower compared to the remaining shared
ORFs and (ii) the LipL homologue, Mra24, is lacking ~60 amino acids at the
C-terminus that contains a His residue that is part of the HX(D/E)XnH motif (X is any
amino acid), which is essential for Fe(II) binding and hence activity. Therefore, it is
highly likely that Mra24 does not encode a functional non-heme Fe(II),
α-KG-dependent dioxygenase.

To provide initial evidence that the correct genetic locus was identified prior to
completion of the sequencing, we introduced cosmid pMra02 into the heterologous
host Streptomyces lividans TK21 with the expectation that this cosmid contains a
genetic element involved in muraminomicin resistance. In contrast to controls using
the empty vector, S. lividans TK21/pMra02 was resistant to muraminomicin at 100 mg
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mL-1 on solid media (Fig 3.3). Retrospective analysis of this cosmid sequence reveals
two potential resistance candidates mra11 and mra16 that encode a putative
ABC-transporter and a protein with similarity to tunicamycin-resistance protein TmrB,
respectively [129]. Although muraminomicin was not produced by the recombinant
strain, a red phenotype was observed upon introduction of pMra02 and
muraminomicin selection, suggesting the cosmid and antibiotic likely up regulate
additional host genes such as those potentially involved in actinorhodin biosynthesis.
Encoded within pMra02 is a protein with similarity to AraC positive regulatory protein,
which may be partially responsible for this phenotypic output. The identity of the
individual genes involved in resistance and regulation is currently under investigation,
nevertheless, the results are consistent with the role of the genetic locus in
muraminomicin production.

S. lividans TK21/pSuperCos-P

S. lividans TK21/pMra02

Figure 3.3. Resistance conferred by pMra02 upon heterologous expression in
Streptomyces lividans TK21.
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3.4. Results: Functional assignment of Mra20 as a low specificity pyrimidine
nucleoside phosphorylase

3.4.1 In vitro characterization of Mra20 activity

Pyrimidine nucleoside phosphorylases catalyze the phosphorolysis of thymidine or
uridine nucleosides to generate 2-deoxy-α-D-ribose-1-phosphate and thymine or
α-D-ribose-1-phosphate and uracil as described for LipP, respectively [130,131].
Although thymidine phosphorylases from several organisms are highly specific for the
2′-deoxyribosyl moiety, some are reported to have very little discrimination at this
position. LipP was slightly specific for the hydroxylated ribose; additionally, efficiency
with 5′-amino-5′-deoxyuridine (2) was comparable to that of uridine (3)[124].

The mra20 gene, which is homologous to lipP, was cloned and expressed in E. coli to
yield soluble protein (Fig 3.4a). Using HPLC for detection, initial activity tests with
Mra20 revealed uridine (3) was converted to uracil (4) and α-D-ribose-1-phosphate
(Fig 3.4b), and identically to LipP [124], the Mra20-catalyzed reaction also proceeded
with 5′-amino-5′-deoxyuridine (2) (Fig3.4c). Additional activity tests revealed
hypothetical

pathway

intermediates

2′-deoxyuridine

(11),

5′-amino-2′,5′-dideoxyuridine (7), thymidine (12) and 5′-amino-5′-deoxythymidine (10)
were

also

converted

to

uracil

(4)

or

thymine

(13)

and the respective

sugar-1-phosphate by Mra20 (Fig 3.5), thus warranting further kinetic investigation.
(a)

(b)
4

3
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(c)
4

2

Figure 3.4. In vitro characterization of Mra20.(a) SDS-PAGE analysis of partially
purified His6-Mra20 (expected MW of 52.5 kD). (b) HPLC analysis using uridine (3)
after 1 hr without Mra20 (I), 1 hr reaction (II) and authentic uracil (4) (III). (c) HPLC
analysis using 5′-amino-5′-deoxyuridine (2)after 1 hr without Mra20 (I), 1 h reaction (II)
and authentic uracil (4) (III). A260, absorbance at 260 nm.

(a)

(b)

(c)
13

4

10

7

12
11

Figure 3.5. Activity of Mra20 with 2′-deoxynucleosides. (a) Phosphorolysis reaction
catalysed by Mra20. (b) HPLC analysis following a 1 h reaction using 2′-deoxyuridine
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(11)
without
Mra20
(I),
2′-deoxyuridine
(11)
with
Mra20
(II),
5′-amino-2′,5′-dideoxyuridine(7) without Mra20 (III), 5′-amino-2′,5′-dideoxyuridine(7)
with Mra20 (IV), and authentic uracil (4). (c) HPLC analysis following a 1 hr reaction
using thymidine (12) without Mra20 (I), thymidine (12) with Mra20 (II),
5′-amino-5′-deoxythymidine (10) without Mra20 (III), 5′-amino-5′-deoxythymidine (10)
with Mra20(IV), and authentic thymine (13).

3.4.2. Kinetics characterization of Mra20

For comparative purposes, single substrate kinetic analysis was performed under the
optimized conditions for LipP using UV/Vis spectroscopy for detection of the free
nucleobase under alkaline conditions. All of the tested substrates displayed typical
Michaelis–Menten kinetics (Fig 3.6), and the extracted kinetic constants revealed that
Mra20 is most efficient with thymine containing nucleosides with little preference for
the C-5′ functional group (Table 8). Although the Km and kcat were both significantly
increased, the efficiency with 2′-deoxyuridinederivatives was quite comparable to the
respective thymine containing nucleoside. Similar to LipP, these kinetic results
suggest that Mra20 has little preference toward any hypothetical pathway
intermediates, and thus cannot be utilized to delineate the timing of the biochemical
events. However, in contrast to LipP, Mra20 has a modest specificity toward the
2′-deoxynucleosides relative to the hydroxylated counterpart, which is consistent with
the observed 5-amino-2,5-dideoxyribosyl moiety that is found in the muraminomicins.
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[11] (μM)

[7] (μM)

[12] (μM)

[10] (μM)

[3] (μM)

[2] (μM)

Figure 3.6. Single-substrate kinetic analysis of Mra20. Data were fitted to the
Michaelis-Menten equation and extracted kinetic constants are given in Table 8.
Table 8. Extracted kinetic constants for Mra20.

Km (mM)

kcat (min-1)

Relative efficiency
(%)

11

1.8 ± 0.3

28 ± 2

61

7

0.87 ± 0.24

16 ± 2

75

12

0.12 ± 0.04

2.9 ± 0.2

100

10

0.13 ± 0.05

3.1 ± 0.3

93

3

0.43 ± 0.07

0.9 ± 0.1

8

2

0.82 ± 0.21

4.0 ± 0.3

19

Substrate

100

3.5. Results: Bifunctional assignment of Mra20 as a potential nucleoside
phosphorylase and cytidine deaminase.

3.5.1 In vitro characterization of Mra20 deaminase activity

Mra20 is most efficient with thymine containing nucleosides as described above
(Table 8). This suggests Mra20 has some specificity for a 2′-deoxy nucleoside. During
our screen of potential substrates, we unexpectedly observed an activity with cytidine.
This observation was unusual since pyrimidine nucleosides phosphorylases that use
uridine or thymidine cannot turnover cytidine. This Mra20 was first confirmed to
catalyze phosphorolysis of cytidine to generate ribose-1-phosphate and a UV-active
base as shown by HPLC (Fig 3.7). Interestingly, the base counterpart generated from
cytidine had the same retention time with uracil instead of cytosine (Fig 3.8).

Figure 3.7. Proposed phosphorolysis reaction with cytidine catalyzed by Mra20.
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Figure 3.8. Activity of Mra20 with cytidine. HPLC analysis following a 1 hr reaction
using cytidine without Mra20 (I), cytidine with Mra20 (II), authentic cytosine (III) and
authentic uracil (IV).

To confirm the product was uracil rather than cytosine, LC-MS was performed to
analyze and distinguish the substrate cytidine and product using authentic uracil and
cytosine as controls. LC-MS analysis of cytosine revealed the expected (M - H)- ion at
m/z = 110.0 and uracil revealed the expected (M - H)- ion at m/z = 111.0. The product
of Mra20reaction starting from cytidine yielded an (M - H)- ion at m/z = 110.9, which
was consistent with uracil and not cytosine (Fig 3.9). 1H-NMR analysis of the Mra20
product demonstrated that the proton signal shift of the product was identical to the
proton signal of uracil compare to cytosine (Fig 3.10). Thus, both LC-MS and 1H-NMR
confirmed that this product is uracil.
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(a)

Cytidine

(b)
ES-API

Cytosine

Neg Scan

(c)

ES-API
Neg Scan

(d)

Cytidine + Mra20

Uracil
ES-API

ES-API
Neg Scan

Neg Scan

Figure 3.9. LC-MS of the Mra20 product with cytidine. (a) Negative ion mass
spectrum for the peak of cytidine. (b) Negative ion mass spectrum for the peak of
cytosine. (c) Positive ion mass spectrum for the peak of the product of cytidine with
Mra20. (d) Negative ion mass spectrum for the peak of uracil.
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(a)

Product of
Cytdine + Mra20

(b)
O
H
H

NH
N
H

O

Uracil
(c)

NH2
H
H

N
N
H

O

Cytosine

Figure 3.10. Characterization product of Mra20-catalyzed cytidine reaction by 1D
NMR. (a) 1H-NMR spectrum of the product of cytidine with Mra20. (b) 1H-NMR
spectrum of uracil. (c) 1H-NMR spectrum of cytosine.

3.5.2. Replacement of O16 with O18 in Mra20-catalyzed cytidine reaction

To further confirm uracil as the product and to explore the deamination mechanism of
cytosine to uracil, O18 was used to replace the H2O (O16) in the Mra20-catalzyed
cytidine reaction. The product was analyzed by LC-MS revealing an (M - H)- ion at m/z
= 112.9, a 2 unite increase compared to uracil, (M - H)- ion at m/z = 111.0. This result
indicated that the origin of new oxygen atom on the 4-carbonyl of uracil originates
from H2O (Fig 3.11).
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(a)

ES-API, Neg, Scan

(b)

m/z
Figure 3.11. Characterization of Mra20-catalyzed reaction using O18. (a) Proposed
reaction of cytidine catalyzed by Mra20 using O18. (b) LC-MS analysis of the product
from the reaction of Mra20 with cytidine (Negative ion mass spectrum ).
3.5.3. Characterization of NH3 production in Mra20-catalyzed cytidine reaction

The results above suggest ammonia is also produced during the conversion of
cytidine to uracil. To confirm that free ammonia (NH3) was produced from this reaction,
glutamate dehydrogenase (GLDH), α-ketoglutarate (α-KG) and NADPH was used in a
coupled enzyme assay. The GLDH catalyzes the reductive conversion of α-KG to
glutamate using NH3 as the source of amine as shown in Fig 3.12a. Since NADPH
has a UV absorption maximum at 340 nm, the reaction was monitored by UV-Vis
spectroscopy by monitoring the decrease in absorbance over a 1 hr reaction. As time
increased, a linear decrease in absorbance was observed indicating the
α-KG-glutamate interchange reaction happened and confirms the existence of free
NH3 (Fig 3.12b).
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(a)

α-KG

Glutamate

(b)

NADPH
NADPH+Mra20
I

II

Figure 3.12. Characterization of NH3 production. (a) Reaction of α-KG and NH3
catalyzed by GLDH to generate glutamate. (b) change of NADPH monitored by
UV-Vis. (I) Control reaction with NADPH, α-KG, cytidine and GLDH added, without
addingMra20; (II) Reaction with NADPH, α-KG, cytidine and GLDH added,
addingMra20.

3.6. Results: Functional assignment
amine-requiringNucleotidylyltransferase

of

Mra23

as

a

primary

Bioinformatic analysis revealed Mra23 has sequence similarity to LipM and other
nucleotidylyltransferases,

enzymes

that

utilize

a

sugar-1-phosphate

and

nucleotide-5′-triphosphate to generate NDP-sugars [132]. The Mra23 homologue from
the A-90289 pathway (LipM) has already been demonstrated to function as a
nucleotidylyltransferase, using 5-amino-5-deoxy-α-D-ribose-1-phosphate and UTP to
generate the activated sugar, and, interestingly, is only able to turn over
ribose-1-phosphate with a 5-amine functionality.

Similarly to Mra20, the gene product of mra23 was soluble when produced in E. coli
(Fig 3.13a). The activity of Mra23 was tested with 2-deoxy-α-D-ribose-1-phosphate or
5-amino-2,5-dideoxy-α-D-ribose-1-phosphate generated in situ by Mra20 from
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2′-deoxyuridine

(11)

and

5′-amino-2′,5′-dideoxyuridine(7),

nucleosides

5′-amino-5′-deoxythymidine (10), thymidine (12), and analysis of these reactions
revealed

a

new

peak

was

formed

only

in

the

presence

of

5-amino-2,5-dideoxy-α-D-ribose-1-phosphate from 5′-amino-2′,5′-dideoxyuridine(7) or
5′-amino-5′-deoxythymidine (10) and UTP (Fig 3.14, Fig 3.13b,c). LC-MS analysis of
the purified new peak revealed an (M-H)- ion at m/z = 517.6, consistent with the
molecular

C14H23N3O14P2

formula

of

UDP-5-amino-2,5-dideoxyribose

UDP-5″-amino-2″,5″-dideoxyribose (8)(expected m/z = 518.1) (Fig 3.14a, Fig 3.15).
We had previously characterized UDP-5″-amino-2″,5″-dideoxyribose (8) by HR-MS
and

complete

NMR

analysis

using

LipP

and

LipM

starting

from

5′-amino-2′,5′-dideoxyuridine(7), and thus co-injections were utilized to confirm the
product of Mra20 and Mra23 (Fig 3.14). In total, the data is consistent with the
function

of

Mra23

as

UTP:5-amino-2,5-dideoxy-α-D-ribose-1-phosphateuridylyltransferase
penultimate catalyst for formation of the disaccharide of muraminomicin.
(a)

(b)
4
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a
as

the

(c)
13

Figure 3.13. In vitro characterization of Mra23 with thymidine (12). (a) SDS-PAGE
analysis of purified His6-Mra23 (expected MW of 29.6 kD). (b) HPLC analysis of the
reaction starting with uridineafter 3 hr without Mra23 (I) and 3 hr reaction (II).
(c)HPLC analysis of the reaction starting with thymidine (12) after 3 hr without Mra23
(I) and 3 hr reaction (II). A260, absorbance at 260 nm.

(a)

(b)
8
4

13

Figure 3.14. Characterization of Mra23 with 5′-amino-5′-deoxythymidine (10). (a)
Enzymatic preparation of the substrate using Mra20, and the reaction catalyzed by
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Mra23 to generate UDP-5″-amino-2″,5″-dideoxyribose (8). (b) HPLC analysis
following a 3 hr reaction starting from 5′-amino-5′-deoxythymidine (10) without Mra23
(I), 5′-amino-5′-deoxythymidine (10) with Mra23 (II), a 12 hr reaction starting from
5′-amino-2′,5′-dideoxyuridine (7) with LipM from the A-90289 biosynthetic pathway
replacing Mra23 (III), and a 12 hr reaction starting from 5′-amino-2′,5′-dideoxyuridine
(7) with LipM coinjected with purified UDP-5″-amino-2″,5″-dideoxyribose (8)
generated by Mra23 (IV).
(a)

(b)

(c)

Figure 3.15. LC-MS of the Mra23 product UDP-5″-amino-2″,5″-dideoxyribose (8)
generated from substrate 5′-amino-5′-deoxythymidine (10). (a) LC analysis of
UDP-5″-amino-2″,5″-dideoxyribose (8) following purification. (b) Negative ion mass
spectrum for the peak at elution time t = 3.5 min. (c) Positive ion mass spectrum for
the peak at elution time t = 3.5min. A260, absorbance at 260 nm.
The substrate specificity of Mra23 is intriguing for a couple of reasons. Firstly, the
transfer

of

ribosyl

units

onto

acceptor

molecules

typically

occurs

with

5-phosphoribosyl-1-pyrophosphate, and the characterization of Mra23 and LipM has
revealed a ribosyl transfer paradigm using NDP-sugars [124]. This realization may
ultimately provide an opportunity to diversify structures by incorporating unnatural
ribosyl units in place of the native sugar via a combinatorial biosynthetic strategy.
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Secondly, several characterized nucleotidylyltransferases are known or have been
engineered by mutagenesis to acceptaminosugar-1-phosphates; however, these
enzymes in general have little discrimination between the amine or hydroxyl
group[118,120,121,122].

Both

Mra23

and

LipM

now

establish

a

nucleotidylyltransferase family whose activity is absolutely dependent upon the amine
functionality, and on-going structural efforts will undoubtedly establish the molecular
details behind this unusual specificity.

The combined results now allow us to define a probable pathway leading to the
disaccharide core starting from either TMP or 2′-deoxyUMP (Fig 3.16). Through an as
of yet unclear mechanism, the 5′-aldehyde is installed to serve as the substrate for the
putative aminotransferase Mra21 to generate 5′-amino-2′,5′-dideoxyuridine (7) or
5′-amino-5′-deoxythymidine (10). Following phosphorolysis of the glycosidic bond by
Mra20, the aminosugar-1-phosphate is activated as the UDP-sugar by Mra20 prior to
transfer to the acceptor molecule, which is most likely 2′-deoxy-5′-C-glycyluridine.

7 or 10
4 or 13

Fig. 3.16. Proposed biosynthetic pathway of the disaccharide core of the
muraminomicins.
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3.7. Results: In vitro characterization of Mra21 activity

Similar to LipO, bioinformatics analysis of Mra21 revealed sequence similarity to
proteins annotated as putative aminotransferase. The potential reaction catalyzed by
Mra21 was shown in Fig 3.17. To interrogate the mechanism of amine group
incorporation, mra21 was first expressed in E. coli, however the recombinant protein
was insoluble using a variety of growth and induction conditions. Therefore, we
turned to Streptomyces lividans TK64 as a host, which resulted in the successful
preparation of soluble, recombinant Mra21 (Fig 3.18a).

Figure 3.17. Proposed reaction catalyzed by Mra21.
Since the true substrate for Mra21 was not available, 5′-aldehyde-uridine (1) was
used as a substitute substrate to test the activity of Mra21 (Fig 3.18b). Unexpectedly,
no new peak was detected after Mra21 incubated with 5′-aldehyde-uridine (1) and
different amino donors, even though several different buffer conditions were tested.
This result suggests Mra21 has specificity for the 2′-deoxynucleoside or, alternatively,
the wrong amino donors were used. Hence further characterization with Mra21is
needed to verify the activity, and efforts are underway to synthesis the potential
substrate 2′-deoxthymidine-5′-aldehyde.
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Mra21
250 kD
150 kD
100 kD
75 kD

50.8 kD

50 kD
37 kD
25 kD

20 kD

Figure 3.18. Characterization of Mra21. SDS-PAGE analysis of purified His6-Mra21
(expected MW of 50.8 kD).

3.8. Results: In vitro characterization of Mra22 activity

We then turned our attention to Mra22, which has sequence identity to a small
number of proteins annotated as putative glycosyltransferases by bioinformatics
analysis. Similar to LipN, Mra22was predicted to transfer a 2′-deoxysugar to the
sugar accepter to generate the final glycoside as shown in Fig 3.19. To test the
activity of Mra22, mra22 was first tried to express in E. coli, however, same as Mra21,
the recombinant protein was insoluble using a variety of growth and induction
conditions. Therefore, Mra22 was tried to express from Streptomycin lividans TK64,
which resulted in the soluble, recombinant Mra22 (Fig 3.20a).
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Figure 3.19. Proposed reaction catalyzed by Mra22.

(a)

(b)
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(c)

(d)
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A260
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Figure 3.20. Characterization of Mra22. (a) SDS-PAGE analysis of purified
His6-Mra22 (expected MW of 45 kD). (b) HPLC analysis of the reaction with
2′-deoxyuridine (11)starting with 5′-amino-5′-deoxythymidine (10) after (I) 3 hr without
Mra22 and (II) 3 hr reaction. (c) HPLC analysis of the reaction starting with
5′-amino-2′,5′-dideoxyuridine(7) after (I) 3 hr without Mra22 and (II) 3 hr reaction. (d)
HPLC analysis of the reaction starting with 5′-amino-5′-deoxyuridine (2) after (I) 3 hr
without Mra22 and (II) 3 hr reaction. A260, absorbance at 260 nm.
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(a)

(b)

(c)

Figure 3.21. HPLC characterization of Mra22. (a) HPLC analysis of the reaction with
uridine (3) starting with 5′-amino-5′-deoxythymidine (10) after (I) 3 hr without Mra22
and (II) 3 hr reaction. (c) HPLC analysis of the reaction starting with
5′-amino-2′,5′-dideoxyuridine(7) after (I) 3 hr without Mra22 and (II) 3 hr reaction. (d)
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HPLC analysis of the reaction starting with 5′-amino-5′-deoxyuridine (2) after (I) 3 hr
without Mra22 and (II) 3 hr reaction. A260, absorbance at 260 nm.

With the soluble protein in hand, the activity of Mra22 was tested with in situ
generation

of

substrate

beginning

from5′-amino-5′-deoxyuridine

(2),

5′-amino-2′,5′-dideoxyuridine (7) and 5′-amino-5′-deoxythymidine (10). HPLC
analysis of Mra22 reactions revealed a new peak while using 2′-deoxyuridine (11) as
surrogate acceptor (Fig 3.20 b, c, d). However, no new peak was detected while
using uridine (3) as surrogate acceptor (Fig 3.21 a, b, c). Although the yield for the
new peak was very low, the product of the peak was purified and finally analyzed by
NMR. However, 1H and 13C NMR analysis of this new peak shown that it was uridine,
rather than the expected compound (data not shown). Thus the true function of
Mra22 needs further investigation.

3.9. Results: In vitro characterization of Mra24 activity

3.9.1. In vitro characterization of Mra24 activity

Similar to LipL, Mra24 has sequence similarity to proteins annotated as putative a
non-heme Fe(II) and α-ketoglutarate (α-KG)-dependent dioxygenase based on
bioinformatics analysis. Previous results have demonstrated that LipL from A-90289
gene cluster is Fe(II)- and α-ketoglutarate (α-KG)-dependent dioxygenase, and UMP
was the only substrate for LipL [88]. Based on this, we hypothesized that
2′-deoxyUMP might be the substrate for Mra24 as shown in Fig 3.22. To investigate
the potential of oxidization process, mra24 was first tried to express in E. coli, and a
soluble protein was obtained (Fig 3.23 a).
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Figure 3.22. Proposed reaction catalyzed by Mra24.
The potential activity of Mra24 was analyzed by HPLC using 2′-deoxyUMP and UMP
as substrates. Unexpectedly, the formation of 2′-deoxyuridne (11) and uridine (3)
was detected instead of an oxidized product after incubation with enzyme (Fig 3.23b,
3.24). This result suggested that Mra24 functioned as a phosphatase instead of
dioxygenase. To confirm these results, we expressed the mra24 gene in S. lividans
TK64, and soluble protein was also obtained. The same reaction was repeated with
the newly purified Mra24 enzyme. Unfortunately, the same results were obtained as
the reaction catalyzed by the enzyme purified from E. coli. Thus, regardless of the
source, it appeared Mra24 functions as a phosphatase, and kinetic studies are
ongoing to ascertain the significance of this activity.
(a)

Mra24
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(b)
I

II

III

IV

V

Figure 3.23. Characterization of Mra24 with 2′-deoxyUMP. (a) SDS-PAGE analysis
of purified His6-Mra24 (expected MW of 28 kD). (b) HPLC analysis of the reaction with
2′-deoxyUMP and Mra24 after (I) 1 hr authentic 2′-deoxyUMP without Mra24, (II) 1 hr
reaction with Mra24, (III) 1 hr authentic 2′-deoxyuridine (11), (IV) 1 hr reaction with
Mra24, without α-KG, (V) 1 hr reaction with Mra24, with EDTA. A260, absorbance at
260 nm.
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I

II

III

IV

V

Figure 3.24. Characterization of Mra24 with UMP. HPLC analysis of the reaction
with UMP and Mra24 after (I) 1 hr authentic UMP without Mra24, (II) 1 hr reaction with
Mra24, (III) 1 hr authentic uridine (3), (IV) 1 hr reaction with Mra24, without α-KG, (V)
1 hr reaction with Mra24, with EDTA. A260, absorbance at 260 nm.

3.9.2. Blast and alignment Mra24 with other dioxygenases

Sequence analysis of Mra24 when compared to dioxygenasesof the same
superfamily showed that Mra24 was lacking ~60 amino acids at the C-terminus. The
C-terminus contains a His residue that is critical for activity due to its role in Fe(II)
binding that is essential for activity (Fig 3.25). Therefore, this might explain why
mra24 does not encode a functional non-heme Fe(II), α-KG-dependent dioxygenase.
Importantly, this suggests that the assembly of the deoxyaminoribose of
muraminomicin has significant differences compared to that for A-90289
biosynthesis. These variations are part of our ongoing research efforts.
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Mra24

Mra24

Mra24

Mra24

Mra24

Figure 3.25. AlignMra24 with similar dioxygenases from other strains. The three red
box stands for the active site for these dioxygenases. Green box showed the miss of
amino acids of Mra24 comparing to other dioxygenases.

3.9.3. Streptosporangiumamethystogenes genomic gene library construction
The blast analysis of the whole gene cluster of muraminomicin showed that Mra24
was the only dioxygenase inside the gene cluster. One possibility was that the gene
encoding the expected dioxygenase function was located elsewhere in the
chromosome. To probe this theory, a Streptosporangium amethystogenes genomic
library was constructed using pJAZZ-OK vector. The recombinant DNA was
transformed into E.coli Bigeasy TSA cells, and primers were to amplify
dioxygenase-encoding genes from genomic DNA. The expedted 520-kb amplified
fragment was obtained and labeled with DIG and used to screen the cosmid library.
Following colony hybridization and southern blot analysis, four positive colonies
were identified and selected for sequencing. Unfortunately, none of the four colonies
showed the right gene sequences for a dioxygenase. Thus, we opted to focus on the
development of a genetic system within the producing strain to ascertain the
significance of individual orfs in muraminomicin biosynthesis.

120

Figure 3.26. Colony Hybridization of Streptosporangiumamethystogenes genomic
gene library using dioxygenase gene probes. Four positive colonies were found after
hybridization.

3.10. Development of a genetic system for in vivo muraminomicin studies

We have successfully characterized two enzymes - Mra20 and Mra23 - involved in the
assembly of the 5-amino-2,5-dideoxyribofuranoside. As for three other enzymes, their
activity and functionality are still unknown – despite the ability to obtain soluble protein.
The results suggested Mra20 and Mra23 played a critical role in the identity of the
aminoribosyl appendage of muraminomicin, yet several questions remained. We
therefore attempted to develop a robust genetic system within the muraminomicin
producing strainas a strategy to further delineate muraminomicin biosynthesis. It is
expected that a genetic system will (i) reconfirm the reactions catalyzed by enzymes
in vitro, (ii) establish an essential role for individual orfs in muraminomicin
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biosynthesis, (iii) verify the identity of the muraminomicin gene cluster, (iv) provide a
platform to rationally design and develop muraminomicin analogues. To carry out this
strategy, the following procedures were conducted.

First, we explored different growth conditions for muraminomicin strain. Unlike
Streptomyces, little information is available on the growth conditions for the
Streptosporangium genus. The limited literature suggest optimal growth may require
oatmeal, metal iron and some other nutritional factors [133][134]. Thus, various
culture media were tested to obtain the best growth and sporulation conditions for
the muraminomicin strain (Table 9).The results suggest the best condition for
Streptosporangium growth was MS medium plus oatmeal, the other medium (ISP2,
R2YE, etc) were not as efficient for attaining a dense culture (Fig 3.27). Furthermore,
the best condition for sporulation was also the oatmeal agar medium, with or without
metals supplemented (Table 9). This growth condition is now being used with the
goal of developing a genetic system.

Table 9. Different culture conditions for Streptosporangium sp. SNAK 60709.
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Figure 3.27. Streptosporangium sp. SANK 60709strain.

We initially targeted the inactivation of mra20 gene of Streptosporangium sp. using a
double-crossover PCR targeting system. Although many conditions were attempted
with this strain, a successful mutant strain was not attainable. Thus, the genetic
system for in vivo muraminomicin studies is still under investigation.

3.11. Conclusion

The biosynthetic gene cluster for muraminomicin has been identified. Two enzymes
involved in the assembly of the aminoribosyl moiety of muraminomicin have been
functionally assigned: Mra20 that catalyzes phosphorolysis to initiate “salvage” of the
aminoribose and Mra23 that activates this sugar for subsequent ribosyltransfer. The
three other enzymes are still under investigation. The established specificity of Mra20
and Mra23 explains at least in part the incorporation of a 2-deoxy and
5-amino-5-deoxy sugar, respectively, into muraminomicin. The results now set the
stage to explore both upstream events, such as the unclear mechanism of
5′-aldehyde formation, and the downstream event of ribosylation. Additionally, the
uncovering of the genetic locus for muraminomicin biosynthetic locus provides further
information for defining a complete biosynthetic mechanism for lipopeptidyl
nucleoside antibiotics.
Copyright © Xiuling Chi 2013
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Chapter four: Summary

MraY (translocase I), one of the key enzymes involved in peptidoglycan cell wall
biosynthesis, is an appealing target for discovering novel bioactive natural products
for clinical use. Lipopeptidyl nucleoside antibiotics, inhibitors of MraY, have been
recently discovered that have excellent anti Gram-positive bacteria activity. The
prominent feature of this family is they all comprise an unusual sugar appendage, a
key component for their antibacterial action. Based upon the bioinformatic analysis
of A-90289 biosynthetic gene cluster, the biosynthetic pathway for aminoribosyl unit
incorporation was firstly proposed and then confirmed by in vitro enzyme
characterization. Five enzymes participated in the assembly of the sugar moiety and
a distinct ribosylation pathway was identified. Uridine-5′-monophosphate was
uncovered as the precursor for using sequential catalysis by a dioxygenase,
aminotransferase, phosphorylase, nucleotidylyltransferase and glycosyltransferase.
This distinctive biosynthetic pathwaywas further confirmed by studies of the
biosynthesis of muraminomicin, whose structure is similar to A-90289. Unlike
A-90289, however, muraminomicin has a unique 2′-deoxy sugar component. The
biosynthetic gene cluster was identified and analyzed by bioinformatics. Two key
enzymes, a phosphorylase and a nucleotidylyltransferase, were characterized in
vitro and exhibited highly similar functionality as the homologous enzymes from
A-90289. The cumulative results in A-90289 and muraminomicin provide valuable
insight into investigating and discovering other lipopeptidyl nucleoside antibiotics and
the preparation of their analogues by combinatorial biosynthetic strategies.

Copyright © Xiuling Chi 2013
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